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Abstract
The 2014-2016 West Africa epidemic was the worst Ebola virus outbreak on record, with the infected
numbering over 28,000 and the dead more than 11,000. Among those who survived the disease, Ebola
virus was found to persist in numerous anatomical locations and be shed in semen. During the West
Africa outbreak, numerous occurrences of Ebola sexual transmission were documented. While sexual
transmission has the potential to compromise public health eradication efforts and reignite outbreaks, no
molecular details of host factors influencing this phenomenon are known. Amyloid fibrils present in
healthy individuals’ semen have been suggested to be a host factor that aids in sexual transmission of
viruses including HIV-1. To understand if seminal amyloid fibrils increase infection by Ebola virus, a
recombinant virus expressing the Ebola glycoprotein was preincubated with the type species of the
seminal amyloids, SEVI. When present, SEVI resulted in a nearly 20-fold increase in infection of
physiologically relevant target cells. SEVI and other seminal amyloids were also found to enhance
authentic Ebola virus infection by 20- to 40-fold in cell culture. Mechanistically, SEVI was found to
increase viral attachment then subsequent internalization of virus through macropinocytosis, a previously
unknown ability to enhance uptake by this mechanism critical for Ebola virus entry. Finally, a new ability of
SEVI to enhance viral stability during incubation at physiologic temperatures and under desiccating
conditions is described, a finding important for transmission biology. Together, these functions of seminal
amyloids represent a first step toward understanding Ebola virus sexual transmission at a molecular level
and provide potential therapeutic targets to prevent transmission by this route.
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ABSTRACT
ENHANCEMENT OF EBOLA VIRUS INFECTION BY SEMINAL AMYLOID FIBRILS
Stephen Michael Bart
Paul Bates

The 2014-2016 West Africa epidemic was the worst Ebola virus outbreak on record, with the
infected numbering over 28,000 and the dead more than 11,000. Among those who survived the
disease, Ebola virus was found to persist in numerous anatomical locations and be shed in semen.
During the West Africa outbreak, numerous occurrences of Ebola sexual transmission were
documented. While sexual transmission has the potential to compromise public health eradication
efforts and reignite outbreaks, no molecular details of host factors influencing this phenomenon are
known. Amyloid fibrils present in healthy individuals’ semen have been suggested to be a host
factor that aids in sexual transmission of viruses including HIV-1. To understand if seminal amyloid
fibrils increase infection by Ebola virus, a recombinant virus expressing the Ebola glycoprotein was
preincubated with the type species of the seminal amyloids, SEVI. When present, SEVI resulted in
a nearly 20-fold increase in infection of physiologically relevant target cells. SEVI and other seminal
amyloids were also found to enhance authentic Ebola virus infection by 20- to 40-fold in cell culture.
Mechanistically, SEVI was found to increase viral attachment then subsequent internalization of
virus through macropinocytosis, a previously unknown ability to enhance uptake by this mechanism
critical for Ebola virus entry. Finally, a new ability of SEVI to enhance viral stability during incubation
at physiologic temperatures and under desiccating conditions is described, a finding important for
transmission biology. Together, these functions of seminal amyloids represent a first step toward
understanding Ebola virus sexual transmission at a molecular level and provide potential
therapeutic targets to prevent transmission by this route.
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CHAPTER 1 – EBOLA VIRUS
Ebola virus was first identified in 1976 in the Central African country of Zaire (now
Democratic Republic of the Congo). Named for the nearby Ebola River, the previously unknown
virus caused a devastating hemorrhagic disease in the area of the village of Yambuku, killing almost
90% of those infected. Over the next four decades, the five Ebolavirus species caused sporadic
and localized outbreaks before the 2014-2016 West African outbreak that infected tens of
thousands.
Section 1.1 – Ebola virus epidemiology
Ebolaviruses, which are Biosafety Level 4 pathogens due to their high pathogenicity, have
collectively caused 29 documented outbreaks in humans worldwide (Figure 1.11–3). Four of the five
viral species in the Ebolavirus genus cause Ebola virus disease (EVD) in humans 4. Ebola Zaire
(EBOV) has caused most identified outbreaks, including both the initial 1976 outbreak and the
2014-2016 West African epidemic, and is the most lethal. Ebola Sudan (SUDV) has also caused
considerable morbidity and mortality, while Ebola Bundibugyo (BDBV) and Ebola Tai Forest (TAFV)
have caused smaller, limited outbreaks. The fifth Ebolavirus, Ebola Reston (RESTV), was identified
in monkeys exported into the United States from the Philippines and causes asymptomatic human
infections that have been identified only by serology5. The Ebolavirus genus, along with its sister
genera Marburgvirus (which contains the eponymous Marburg virus, MARV) and Cuevavirus
(which contains a single species identified only by sequencing of European bats and never
isolated6), comprise the Filoviridae family. Discounting RESTV, Ebolavirus outbreaks have
originated exclusively in sub-Saharan Africa, though spread to Europe and North America has
occurred. Case-fatality ratios for the various outbreaks involving human-to-human transmission
have ranged from 36-90%2. Most outbreaks have been relatively small and contained to remote
areas, with the West Africa EBOV outbreak being the exception.
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Figure 1.1. Ebola virus outbreaks, 1976-present.
Ebola virus disease outbreaks (excluding accidental laboratory exposures) are indicated by
colored circles at the site of the index case, with larger circles indicating more cases. Countries
reporting at least one human Ebola virus case are colored in dark gray.
The 2014-2016 West African outbreak is by far the deadliest Ebola outbreak on record.
The official totals for the outbreak, which are almost certainly underestimates of the true disease
burden, tally 28,652 cases and 11,325 deaths, a case-fatality ratio (CFR) of 39.5%2. The index
case of the outbreak is believed to be a 2-year-old child who died in December 2013 in Meliandou,
Guinea7. This region of Guinea has been heavily deforested and mined, and it is hypothesized that
habitat destruction may have exposed the EBOV reservoir to the human population 8. The virus
spread to the boy’s family and to others from surrounding villages before reaching the neighboring
countries of Liberia and Sierra Leone by March 2014 9. Over the next few months, the virus began
spreading through major population centers, including the capital cities of Monrovia, Liberia;
Conakry, Guinea; and Freetown, Sierra Leone. Poor sanitation within urban slums contributed
greatly to the spread of the virus10. West Africa has not historically been a site of widespread Ebola
outbreaks in the past, and the most heavily affected countries were ill equipped to respond to the
outbreak.
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The virus spread to several nearby countries, including Senegal, Nigeria, and Mali, as well
as outside Africa, with cases being diagnosed in Spain, Italy, the United Kingdom, and the United
States11. These countries exhibited very limited viral spread relative to the most heavily affected
countries of Guinea, Liberia, and Sierra Leone (Figure 1.2).
The particular strain of EBOV causing the outbreak was named the Makona strain and was
found to be 97% similar to EBOV isolates from the Democratic Republic of the Congo (DRC) and
Gabon7,12. The strain clusters phylogenetically with the other Zaire ebolavirus species, with about
400 nucleotide differences across the 19 kb genome separating it and the 1976 EBOV-Mayinga
strain7. Genomic sequencing confirmed that the outbreak was monophyletic and appeared to
initiate from a single introduction of the virus into the human population followed by sustained
human-to-human transmission9.
EBOV is transmissible from the beginning of the symptomatic phase, and the infected can
transmit virus even after death. EBOV is highly infectious; as few as 1-10 aerosolized particles are

Figure 1.2. Affected countries, 2014-2016 Ebola outbreak.
Map showing the countries reporting cases of Ebola virus disease during the outbreak initiating
in West Africa. Darker shades of blue indicate higher numbers of confirmed EVD cases.
3

lethal in non-human primate models of EBOV infection13. The main route of transmission is through
contact with infected bodily fluids. Those caring for infected relatives and those involved in
preparation of bodies for burial are at particular risk for EBOV transmission; the latter was
particularly important during the West African outbreak 14. This method of exposure is thought to
have played a major role in the spread of the virus before public health measures alleviated this
transmission route.
The reservoir for Ebolaviruses between outbreaks has yet to be definitively identified,
though evidence suggests that fruit bats are the most likely culprit. EBOV RNA and antibodies have
been detected among African bat populations, and seroprevalence of EBOV antibodies increases
in bat populations during human outbreaks15-17. Further, MARV, a related filovirus, has been
isolated from African bat species18. Notably, the index case of the West Africa outbreak was
reported to have been playing in a hollow tree that harbored a large bat population before his
symptoms began19. Bats do not show symptoms of disease despite high levels of EBOV in the
blood20. Virus has been found in various wild animal carcasses, including gorillas, chimpanzees,
and duikers, indicating that infection is not limited to humans 21. EBOV outbreaks among
chimpanzees and gorillas have led to large declines in their populations22,23. Swine have been
documented as hosts for RESTV in addition to monkeys as previously described24. The role of
domestic animals as vectors of EBOV transmission is unclear. During a 2002 outbreak of EBOV in
Gabon, 30% of dogs were seropositive for EBOV, though the specificity of the assay used is
questionable25. No disease was documented in these animals, and in vitro experiments suggest
that canine cells are less susceptible to EBOV infection than primate cells (Box 1)26, leaving the
role of domestic animals in EBOV transmission an open question.
While EBOV has clearly evolved on a genetic level between the 1976 outbreak and the
present, there have been no notable changes in viral characteristics over time 27. However, due to
the high degree of person-to-person transmission in the 2014-2016 outbreak, it was hypothesized
that mutations may have arisen in the virus as it adapted to humans rather than its natural host.
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One such mutation, at position 82 in the EBOV glycoprotein, arose during the outbreak and was
subsequently found to increase infectivity of the virus in culture 28–30. The increase in infectivity,
however, comes at a cost to the virus, resulting in decreased glycoprotein stability under
physiological temperatures30. Bats have a higher physiological temperature than humans (due to
the higher metabolic rate necessary for flight), potentially explaining why the mutation has not been
previously seen in outbreaks with less-extensive human-to-human EBOV transmission.

Section 1.2 – Ebola virus biology
The EBOV virion is a long, filamentous, enveloped particle of variable length (600 to 1400
nm) and a uniform diameter (80 nm)31. The EBOV genome comprises a single strand of negativesense RNA divided into 7 genes encoding 9 proteins31 (Figure 1.3). The genome is packaged within
a ribonucleoprotein (RNP) structure composed of nucleoprotein (NP), minor nucleoprotein (VP30),
and the polymerase complex (L/VP35). The RNP is enclosed within a matrix composed of the
matrix protein VP40 and the minor matrix protein VP24. The glycoprotein (GP1/GP2, or EboGP) is
the only virion surface protein and effects attachment to target cells and fusion of the virion and
cellular membranes. EboGP is thus the target of the neutralizing antibody response in infected
individuals. Additionally, cells infected with EBOV produce two other nonstructural products from
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Figure 1.3. Schematic of EBOV genome organization and virion structure.

the glycoprotein gene, the secreted glycoprotein (sGP) and small secreted glycoprotein (ssGP).
These products share a portion of sequence with EboGP; mRNA production for each is a result of
mRNA editing by polymerase slippage or stuttering, with sGP being the main gene product32,33.
The function of these soluble glycoproteins is unclear, but they may assist in evading the host
antibody response34,35. EboGP and VP40 together are sufficient to produce filamentous virus-like
particles (VLPs) which can mimic the entry process for authentic EBOV36–38.
EBOV undergoes a unique and complex entry process to infect cells 39 (Figure 1.4). The
first step of viral entry is attachment to the surface of cells by generally nonspecific mechanisms
with cellular attachment factors40. Characterized interactions include binding of carbohydrates on
EboGP to C-type lectins such as DC-SIGN and DC-SIGNR41 and direct or indirect binding of
phosphatidylserine (PS) in the virion membrane with cellular receptors. These cellular PS receptors
include members of the Tyro3 family of receptor tyrosine kinases (e.g. Axl) and the T cell
immunoglobin and mucin domain family (e.g. TIM-1)42–46. These attachment factors are abundant
on dendritic cells (DCs) and macrophages, which represent important early cell types for EBOV
infection. Interestingly, it is hypothesized that the PS-mediated attachment process reflects
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“apoptotic mimicry,” as apoptotic blebs also present PS on their outer lipid leaflet and are cleared
by antigen-presenting cells such as DCs and macrophages47. Intact cells employ flippases to
maintain PS on only the inner leaflet of the plasma membrane and avoid recognition through this
mechanism.
Attachment to the surface of the cell triggers the virion internalization by macropinocytosis,
a relatively nonspecific uptake mechanism involving actin dynamics and membrane ruffling 38,48,49.
Within the cellular endosomal network, the virion requires the activity of the Rab GTPases Rab5
and Rab7 to traffic to a low pH compartment49. There, cellular cathepsin B/L proteases process
EboGP, removing part of the glycoprotein and exposing a receptor-binding domain to permit the
glycoprotein to interact with the cellular cholesterol transporter Niemann-Pick C1 (NPC1) within the
late endosome50–54. This binding event is necessary to trigger a conformational change within the
glycoprotein, which results in the fusion of virion and cellular membranes and the release of the
RNP into the cytoplasm. Within the cytoplasm, the polymerase transcribes and replicates the
genome, leading to production of new EBOV particles budding from the plasma membrane.

Figure 1.4. Schematic of EBOV entry into cells.
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Section 1.3 – Ebola virus disease
When EBOV was first described in 1976, the disease it caused was termed Ebola
hemorrhagic fever (EHF) due to the severe bleeding seen in some patients. Because only a fraction
of individuals exhibit hemorrhagic symptoms, EHF has been rechristened Ebola virus disease
(EVD). The incubation period lasts 2-21 days4. Individuals can transmit the virus as soon as they
are symptomatic, and the first phase of disease is marked by non-specific symptoms typical of viral
infections (chills, fever, myalgia, etc)4,55. The second phase encompasses additional symptoms
including lethargy, nausea, vomiting, abdominal pain, anorexia, diarrhea, coughing, headache, and
hypotension4,55. Hemorrhage is observed in a minority of cases 4,55. In severe cases, multi-organ
failure affecting the cardiovascular, respiratory, and renal systems; hepatic injury; and hypotensive
shock can contribute to death 6-16 days after onset of symptoms4,55. Viral RNA and antigen can be
detected in the blood during the symptomatic phase of disease, and antibodies against the virus
can be detected by serology during and after symptomatic disease56,57.
In non-human primate models, the first cells in which EBOV antigen can be detected are
DCs and other cells of the monocyte/macrophage lineage 58. In a guinea pig model of infection,
macrophages positive for the EBOV genome can be detected by in situ hybridization (ISH)
throughout the disease course in multiple anatomical sites 59. Trafficking of these cells to lymph
nodes and through blood is hypothesized to be a mechanism for spread of EBOV throughout the
body to other target cells and organs60. Understanding of human pathology is limited by the paucity
of autopsies due to biosafety concerns 61. Hepatocytes are a major target cell for EBOV infection,
and hepatic necrosis is observed in fatal EBOV cases61. Other cell types found infected by EBOV
in humans include epidermal DCs, endothelial cells, and connective tissue fibroblasts in the skin61.
The only cells characterized as resistant to EBOV infection are lymphocytes, though they are
severely depleted during infection in a mechanism potentially involving TLR462–65. Severe cases of
disease are marked by massive releases of pro-inflammatory cytokines and vasodilators, which
likely contributes to pathology66. Recent retrospective analysis of existing guinea pig model tissues
indicates that numerous cell types are infected that have not been previously appreciated, including
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(among others) the endocardium, Schwann cells of the peripheral nervous system, smooth muscle
of the vaginal wall, and the epithelium of the vagina and penis67. Infection at these previously
overlooked sites may play critical roles in persistent infection (Section 1.4) and sexual transmission
(Section 1.5).
Some proportion of individuals exposed to EBOV develop an antibody response while
experiencing no or only mild symptoms. While determination of this fraction is complicated by
disparate serological profiles among African populations, recent estimates suggest that a small
percentage (2-11%) of those serologically positive for EBOV did not show symptoms of disease68,69.
Individuals are apparently able to transmit virus to others even in the absence of any symptoms 70.

Section 1.4 – Post-Ebola syndrome and persistence
A constellation of symptoms, referred to as post-Ebola syndrome, has been described
among EVD survivors. These symptoms are variable and include headache, ocular pain and vision
loss, impotence, hearing loss, arthralgia, myalgia, extreme fatigue, anorexia, and neurological
complications. Among a small cohort of survivors, all reported at least one post-Ebola symptom,
with headache being most common and reported by a majority of subjects 71. As early as 1977,
when a researcher accidentally infected himself with SUDV and fell ill with EVD, it was known that
Ebolaviruses could persist even after recovery from disease72. Even in the absence of symptoms

Figure 1.5. Summary of evidence of filovirus persistence in semen.
9

and after EBOV has been cleared from blood, EBOV can persist in immune privileged sites
including the central nervous system, eye, mammary glands, and the reproductive system. EBOV
RNA has been detected in semen 2.5 years after disease (Figure 1.5)73, and persistence in vaginal
fluids has been documented 33 days post-symptom onset74.
The issue of persistence came to the forefront during the 2014-2016 West Africa epidemic,
during which it was appreciated that persistent virus could cause significant issues including uveitis,
meningoencephalitis, and sexual transmission. Ocular problems, including uveitis, blindness,
cataracts, and retinal scarring, can be debilitating and correlate with inflammation from persistent
infection75. One man exhibited a change in eye color associated with persistent EBOV in his eye
months after his recovery from acute disease76. A woman in the UK suffered from
meningoencephalitis due to a resurgence of EBOV that was genetically identical to the virus she
had survived months before, even though she had developed EBOV antibodies77. Perhaps most
worrying, however, is the potential for transmission of persistent virus to reignite an outbreak in the
absence of surveillance mechanisms. A case of suspected transmission from mother to child by
breastfeeding was reported involving a mother who had not shown symptoms of EVD but harbored
EBOV RNA in her breastmilk70. Further, studies prior to, during, and after the 2014 outbreak have
demonstrated that filoviruses could persist and be shed in semen for weeks to months following
infection. For the first time, several cases of EBOV sexual transmission were reported during the
2014 outbreak, and cohort studies assessed the length of time that EBOV could be detected in
semen (Figure 1.572–74,78–93). EBOV RNA has been detected in semen up to 965 days following
infection, though the presence of EBOV RNA does not necessarily imply the presence of infectious
virus74. Cultivation of EBOV from semen is complicated by semen’s cytotoxic character and
contamination with bacteria and fungi90,94, but infectious virus has been identified from semen
collected up to 233 days following EVD by injection into SCID mice90.
The cell types that sustain persistent EBOV infection have not been well defined in
humans. Persistent infection likely occurs in tissues that were infected during acute disease but
failed to clear the virus. Relevant to persistence and shedding of EBOV in semen, EBOV antigen
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has been detected in the seminiferous tubules, testicular endothelium, and blood vessels of the
male reproductive system in an EBOV case61. Infection of monkeys shows replication within the
interstitial cells of the testis95. Monkeys that survived EBOV infection either naturally, after
vaccination, or after treatment with investigational antivirals showed evidence of viral persistence96.
Mirroring reports of disease in humans, EBOV RNA and antigen was observed in these archived
rhesus macaque brain, eye, and epididymis samples weeks after infection96. Immunofluorescence
microscopy indicated that tissues infected with persistent EBOV had high levels of infiltration by
CD68+ cells, which are cells of the monocyte/macrophage lineage and known targets for EBOV
infection96. Both EBOV genome and antigenome were detected by fluorescence in situ
hybridization in a macaque epididymis sample and EboGP was detected both inside and outside
of cells by immunofluorescence96. These data suggest ongoing replication and perhaps virion
production at the time of death.

Section 1.5 – Ebola sexual transmission
In 1968, a doctor returned to Marburg, Germany after contracting an unknown hemorrhagic
disease in Africa. Two months after he recovered, he transmitted the virus, then christened MARV,
to his wife by sexual transmission and initiated a small outbreak93. His semen was found to be
infectious in a guinea pig model93. Sexual transmission of EBOV had never been rigorously
demonstrated before the 2014 Ebola outbreak, when several substantiated incidents of male-tofemale EBOV sexual transmission of this persistent virus were reported. The first documented
occurrence was in Liberia in 2015 when a man who survived EVD sexually transmitted EBOV to
his wife 180 days following his illness79. While no infectious virus was isolated from his semen,
EBOV RNA was detected79. The wife’s virus was found to be highly similar to the husband’s virus,
and phylogenetic analysis showed that the wife’s virus clustered not with the currently circulating
EBOV isolates but instead with sequences from the village when the husband was ill79. EBOV
sexual transmission seems to be an uncommon event, as another woman with whom the husband
had sexual relations apparently did not contract the virus 79. The finding that EBOV could be sexually
transmitted for months after recovery from the virus led the WHO to extend their guidance to EVD
11

survivors to use safer sex practices for one year after their disease. Genomic sequencing data
have been used to identify transmission chains with evolution rates that are much lower than would
be expected, a marker for transmission of persistent EBOV. This strategy has been used to identify
previously overlooked clusters of EBOV sexual transmission97.
While most sexual transmission events have not been extensively documented and remain
relatively uncommon, published cases demonstrate potential major public health concerns. A
modeling study predicted that a three-month infectious period could extend the outbreak by 83
days, though many of the model criteria were estimated in the absence of reliable data98.
Importantly, once the virus has been transmitted from a persistently infected source, it can be
spread through normal mechanisms of contact with bodily fluids. This raises the specter of sexual
transmission reigniting an outbreak in an area declared free of EBOV transmission, a scenario that
occurred in Guinea in early 2016. In December 2015, Guinea was declared Ebola-free, but several
months later in March 2016, a cluster of seven cases was identified that further spread into
Liberia81. Independent genomic sequencing and epidemiological investigations converged on the
conclusion that the outbreak was due to sexual transmission of persistent EBOV in a man who had
EVD 470 days prior81. Notably, this man had observed the WHO guidelines and abstained from
unprotected sexual contact for one year after his disease, suggesting that the guidelines were
insufficient to prevent reignition of EBOV transmission chains. The guidelines also suggest that
male survivors should have their semen tested for the presence of EBOV until negative, and
screening programs have been set up to provide counseling and monitor seminal persistence
among survivors99.

Section 1.6 – Ebola virus disease treatment and prevention
Treatment for EVD is primarily supportive in nature and no approved therapies exist. Trials
for some specific therapeutics were conducted during the West Africa outbreak, though issues of
sample size arose as the outbreak waned in addition to ethical concerns 100,101. The standard of
care for EVD, hydration and electrolyte replacement therapies, counteracts the effects of vascular
leak and diarrhea102. Because survivors of EVD develop neutralizing antibodies against EboGP,
12

plasma from surviving individuals (convalescent plasma) has been considered as an experimental
treatment since the 1970s72. In an uncontrolled case series of 8 patients treated with convalescent
plasma in a 1995 EBOV outbreak in the DRC, 7 survived; the CFR of 12.5% among treated patients
was much lower than the overall outbreak CFR of 80%103. However, a recent trial of 99 patients
showed no statistically significant difference in risk of death among EVD patients treated with
convalescent plasma compared to controls, though there may have been a benefit among pediatric
patients104. Notably, the plasma used for this trial was not tested for neutralizing capacity before
infusion. Cocktails of monoclonal antibodies against EboGP have yielded promising results in
preclinical trials in non-human primates and were used both under compassionate use settings and
in trials during the outbreak. ZMapp, a cocktail of three human-mouse chimeric monoclonal
antibodies, was administered to several patients outside of Africa; a majority survived 101. A clinical
trial demonstrated that treatment with ZMapp resulted in a 40% decrease in relative mortality
among EVD patients, though this difference did not reach predetermined benchmarks to consider
the treatment superior to standard of care105. A cocktail of three mouse monoclonal antibodies,
ZMAb, has been used in Europe to treat two patients, both of whom survived 101. No further data is
available on its efficacy in humans.
Numerous small molecule treatments have been developed to inhibit EBOV replication, but
few have been tested in humans. Favipiravir, which is licensed in Japan to treat influenza, has been
described to also have activity against other negative-strand viruses by targeting the viral RNAdependent RNA polymerase106. Most EBOV patients treated in Europe received favipiravir. A nonrandomized, historically controlled trial suggested that favipiravir may be efficacious in patients with
high viral titers107. A clinical trial is ongoing to observe the effects of favipiravir in men whose semen
remains positive for EBOV after recovery108. Another therapy, TKM-Ebola, is composed of multiple
short interfering RNA molecules (siRNAs) targeting the EBOV genome. While phase I trials were
halted due to cytokine abnormalities among participants, two patients in the US received the drug
along with convalescent plasma and both recovered109. The efficacy of the treatment, however, is
unknown. The last treatment used in humans during the 2014 outbreak is brincidofovir, a drug that
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targets DNA virus DNA polymerases and shows activity against EBOV in vitro through an unclear
mechanism110. Brincidofovir was used to treat one patient in the US and entered phase II trials
during the outbreak, but the trials were halted due to declining case numbers101,111.
Finally, several vaccine candidates have arisen over the past few decades. The most
advanced use viral vectors engineered to express EboGP. A phase III trial of a vaccine composed
of vesicular stomatitis virus with its own glycoprotein replaced with EboGP showed 100% efficacy
(95% CI 74.7-100%) when contacts of infected individuals were vaccinated immediately after
identification in a ring vaccination strategy112. However, numerous adverse events have been
identified among those vaccinated113. Another vector vaccine, which uses a chimpanzee
adenovirus to express EboGP followed by a boost with modified vaccinia Ankara expressing
EboGP, has not completed phase III trials but effectively produces both humoral and cellular
responses in study participants114.
Given the high morbidity and mortality associated with EVD, the continued development of
antiviral agents – both therapeutic and prophylactic – is of high priority.
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CHAPTER 2: SEMINAL AMYLOID FIBRILS
Amyloid fibrils are traditionally considered pathologic in nature, being associated with
degenerative diseases including Alzheimer’s disease, prion diseases, and amyloidosis. In these
cases, proteins adopt a fold that renders them remarkably stable and insoluble, leading to toxic
protein aggregation. It has recently been discovered that amyloid fibrils are present in healthy
individuals and may play an important physiological role. However, like many existing host factors,
viruses may hijack them to facilitate their own transmission and replication.
Section 2.1 – Introduction to seminal amyloids
The role of semen in sexual transmission of viruses has long been unclear. Semen had
traditionally been thought to act only as a passive vehicle for the virus, but studies have suggested
that it may play direct roles in enhancing human immunodeficiency virus type 1 (HIV-1) infection
by pH neutralization1,2, opsonization3, and recruitment of target cells to the female genital tract 4,5.
To identify additional pro-viral mechanisms, a library of peptides and small proteins derived from
human semen was screened for factors that modulate HIV-1 infection6. This screen led to the
identification of fractions that increased HIV-1 infection, and mass spectrometry identified those
fractions as containing a peptide derived from prostatic acid phosphatase (PAP) 6. PAP is a major
proteinaceous component of semen and is present at 1-2 mg/mL; a 39-amino acid peptide,
PAP248-286, was recovered at a concentration of 35 μg/mL in semen6. Unexpectedly, when this
peptide was chemically synthesized, it had no effect on viral infection. It was not until the solutions
became turbid after short-term agitation or incubation that a pronounced enhancement in viral
infectivity was noted6. Interestingly, when the turbid solution was analyzed, it was found that the
PAP248-286 peptides had oligomerized into amyloid fibrils that were termed semen-derived
enhancer of viral infection (SEVI)6. Amyloid formation was confirmed by electron microscopy and
increases in fluorescence upon incubation with the amyloid-binding dyes thioflavin T and Congo
red6.
SEVI was found to dramatically enhance the ability of HIV-1 to infect reporter cell lines and
primary cells6. The enhancement effect was found to be greater at low virus concentrations, a
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conclusion supported by viral titration experiments indicating a 10 5-fold enhancement in viral titer6.
Because HIV-1 infectivity is limited by poor attachment to host cells, likely contributing to the finding
that less than 0.1% of viral particles are infectious in vitro7,8, this level of enhancement may be very
significant in terms of disease transmission. The presence of SEVI fibrils was found to reduce the
number of virions required to establish a productive infection in cell culture by several orders of
magnitude, from 103-105 down to 1-3 virions6.
Subsequent studies have found that SEVI is not the only amyloid present naturally within
semen. Another fragment of PAP, PAP85-120, is present at a similar concentration in semen and
was also found to enhance infection by HIV-19. Amyloidogenic fragments of the seminal proteins
semenogelin-1 and -2 (SEM1 and SEM2)10, which are important components of the seminal
coagulum, have also been found to enhance HIV-1 infection in vitro. The semenogelin proteins are
cleaved by prostate specific antigen (PSA)10; the protease responsible for liberation of PAP85-120
and PAP248-286 fragments is unknown but may originate in the seminal vesicles 10.
Section 2.2 – Mechanism of enhancement by seminal amyloids
All seminal amyloids described to date are highly basic. The PAP248-286 peptide which
forms SEVI has a theoretical isoelectric point of 10.21 owing to its high proportion of positively
charged residues (8 of 39 are lysine or arginine)6. This positive charge is essential for viral
enhancement. Replacement of all positive residues on PAP248-286 with alanine does not impact
its ability to form fibrils but abrogates its ability to enhance HIV-1 infection11. Further, treatment of
the fibrils with anionic polymers such as dextran sulfate or molecular tweezers that mask the
positively charged residues abrogates enhancement ability11,12. Combining these results with the
observations that freshly dissolved peptide does not enhance viral infection, both positive charge
and amyloid character are necessary for enhancement but neither is sufficient alone.
Live-imaging microscopy has revealed that SEVI fibrils are captured by cellular protrusions
at the plasma membrane6. It is hypothesized that the positively charged PAP248-286 fibrils are
liberated from PAP by proteolytic cleavage and assemble into SEVI fibrils (Figure 2.1). These fibrils
bind virion membranes through interactions with negative charges on the virion membrane. The
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Figure 2.1. Model of enhancement of HIV-1 infection by SEVI. .
6

SEVI fibrils then interact with target cells in a similar way, bringing the virion into close proximity
with the cell membrane. In this way, attachment to the cell is enhanced, leading to increases in
downstream entry processes including viral fusion6. The interaction between the seminal amyloids
and virion membranes appears to be glycoprotein-independent to some degree. Similar foldincreases in cellular attachment have been observed with VLPs formed by the HIV-1 glycoprotein
and matrix protein p24 and particles formed with p24 alone without a glycoprotein 6. Seminal
amyloids have been further characterized to enhance infection by HIV-1, HIV-2, simian
immunodeficiency virus (SIV), cytomegalovirus (CMV), herpes simplex virus (HSV), and
pseudoviruses bearing various glycoproteins on an HIV-1 core13–17. Enhancement may occur
similarly for all enveloped viruses with similar membrane composition. Electron micrographs
demonstrate internalization of SEVI fibrils into the cell in the absence of virus, suggesting that the
fibrils may induce their own internalization6. However, inhibitors of phagocytosis were not sufficient
to block the enhancement effect observed for HIV-1, which may fuse at the cell surface6.
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Section 2.3 – Seminal amyloids and function
The physiological role of seminal amyloids has not been conclusively demonstrated. Sperm
cells fluoresce when stained with Congo red, an amyloid-specific dye, suggesting that they may be
coated in seminal amyloids18. SEM-1 and SEM-2 have been observed to bind to spermatozoa by
immunofluorescence, though it is unclear whether the fraction of these proteins binding is formed
into amyloid fibrils19. These proteins are under strong positive selection, suggesting these proteins
may have an important role in evolutionary fitness20,21. Indeed, given the ability of these fibrils to
enhance viral infection, one may posit that they may be evolutionarily selected against unless
serving another function. Indeed, phylogenetic analysis suggests that these fibrils are conserved
among primates, and the analogous peptide to SEVI in macaques enhances viral infection 22,23. It
has been hypothesized that seminal amyloids enhance fertilization through a similar mechanism
by which they enhance viral infection. In analogous cases, a much smaller membrane-bound
particle (sperm cell or enveloped virus) must overcome charge repulsion between its membrane
and its target (egg cell or susceptible host cell). Both scenarios are often dependent upon lipid rafts
and involve the action of glycoproteins to fuse membranes24. Interestingly, many compounds
developed to inhibit fertilization will also inhibit viral infection to some degree, and vice versa 24.
Recent experiments, however, have demonstrated that seminal amyloids (SEVI and
SEM1) actually inhibit fertilization of mouse gametes 25. Subsequently, it was found that binding of
amyloid fibrils restricted movement by spermatozoa25. In addition, treatment of spermatozoa with
seminal amyloid fibrils was found to increase their internalization by macrophages, especially if the
spermatozoa had been damaged by freeze-thaw cycles25. This led to a revised hypothesis that
seminal amyloids may bind damaged or less fit spermatozoa and promote their clearance by
phagocytic cells resident in the female genital tract. Interestingly, these same cell types are targeted
for infection by several sexually transmitted viruses including EBOV, and the hypothesis that
seminal amyloids may enhance their infection by a similar mechanism is untested.
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Section 2.4 – Targeting amyloid fibrils
Heterosexual sexual transmission of HIV-1 and some other sexually transmitted viruses
appears to be a relatively rare event. While HIV-1 transmission is highly dependent on viral load,
studies suggest that transmission probabilities range from 0.01% to 0.23% per act26. Because these
rates are very low, especially in the context of the huge burden of HIV-1 disease, even modest
decreases in these rates may have large impacts on prevention of HIV-1 transmission. Because
seminal amyloids are able to greatly enhance viral infection in vitro, the development of compounds
that reduce this enhancement effect has been explored. Many of these strategies interfere with
amyloid formation, stability, interaction with viral particles, or a combination of these27.
Many compounds have been explored to prevent the interaction of SEVI with viral particles,
often by shielding the highly positive charge of the amyloid. Heparan sulfate and other polyanions
have been shown to disrupt the interaction between SEVI and HIV-1 particles in addition to direct
activity against HIV-111,28,29. Unfortunately, these molecules had detrimental effects in clinical
settings due to induction of inflammatory responses that resulted in an increase in HIV acquisition 30.
A similar strategy is to treat cells with molecules that antagonize the interaction between SEVI and
the polyanions on the cell surface such as heparan sulfate proteoglycan. Surfen, such an
antagonist, inhibits both interactions between the amyloid and cellular membrane as well as
between the amyloid and viral membrane31. Another strategy has involved use of molecular
tweezers that specifically bind arginine and lysine residues, shielding their positive charge from the
virion. These molecules inhibit enhanced HIV-1 infection both through this mechanism and through
direct antiviral effects on HIV-1 and other viral membranes12. This strategy is particularly attractive
as it acts on both the virion and a host factor, making it unlikely that the virus will be able to evolve
resistance to this mechanism.
Inhibition of the formation of precursor peptides into amyloid (e.g. PAP248-286 into SEVI
fibrils) is a strategy that takes advantage of the observation that soluble peptides have no impact
on viral infection. One such strategy is to design non-natural peptides that are able to interact with
the amyloidogenic peptide but sterically block amyloid assembly. A computationally designed
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peptide, WW61, was found to be able to prevent PAP248-286 from assembling into SEVI fibrils32.
However, because fibrils are present in their amyloid state in semen33, such a strategy may not be
viable to prevent enhancement of viral infection in vivo. Epigallocatechin-3-gallate (EGCG), an
antioxidant isolated from green tea, has been shown to disassemble SEVI fibrils slowly (over the
span of 1-2 days) and prevent formation of PAP248-286 peptides into fibrils34. Again, it is unclear
whether this strategy would be viable in vivo over such a timescale.
A final strategy is to remodel amyloid fibrils, either by disassembling the amyloid structure
or by altering the conformation to one that does not enhance viral infection. In addition to EGCG
described above, work has been done exploring the ability of disaggregase proteins to act upon
amyloid substrates (Box 235). Hsp104, a yeast AAA+ protein, is able to both resolve and refold
disordered protein aggregates and remodel amyloid fibrils 36. It was found that Hsp104 is able to
remodel SEVI, SEM1, and PAP85-120 amyloid fibrils in an ATP-dependent fashion to prevent
enhancement of infection35. Interestingly, a mutant Hsp104 that was unable to hydrolyze ATP was
still able to remodel the seminal amyloids into clusters that did not enhance HIV-1 infection35. This
is particularly important because ATP is present at very low levels in the extracellular space. Thus,
disaggregase proteins may represent a useful strategy for reducing the infection enhancement
ability of amyloid fibrils.
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Section 3.1 – Abstract
The 2014 Western Africa Ebola virus (EBOV) epidemic was unprecedented in magnitude,
infecting over 28,000 and causing over 11,000 deaths. During this outbreak, multiple instances of
EBOV sexual transmission were reported, including cases where the infectious individual had
recovered from EBOV disease months before transmission. Potential human host factors in EBOV
sexual transmission remain unstudied. Several basic seminal amyloids, most notably semenderived enhancer of viral infection (SEVI), enhance in vitro infection by HIV and several other
viruses. To test the ability of these peptides to enhance EBOV infection, viruses bearing the EBOV
glycoprotein (EboGP) were preincubated with physiological concentrations of SEVI before infection
of physiologically relevant cell lines and primary cells. Pre-incubation with SEVI significantly
increased EboGP-mediated infectivity and replication in epithelium- and monocyte-derived cells.
This enhancement was dependent upon amyloidogenesis and positive charge, and enhancement
was observed with both viruses carrying EboGP and authentic EBOV. SEVI enhanced binding of
virus to cells and markedly increased its subsequent internalization. SEVI also stimulated uptake
of a fluid phase marker by macropinocytosis, a critical mechanism by which cells internalize EBOV.
We report a previously unrecognized ability of SEVI to significantly alter viral physical properties
critical for transmissibility by increasing the stability of EboGP-bearing recombinant viruses during
incubation at elevated temperature and providing resistance to desiccation. Given the potential for
EBOV sexual transmission to spark new transmission chains, these findings represent an important
first interrogation of factors potentially important for this novel EBOV transmission route.
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Section 3.2 – Significance Statement
During the 2014-2016 Ebola outbreak, multiple instances of male-to-female sexual transmission of
Ebola virus (EBOV) were reported. While relatively uncommon, EBOV sexual transmission
presents a major public health concern, as these transmission events occurred months after
recovery. Further, sexual transmission was linked to a resurgence of EBOV disease in Guinea,
which had previously been declared Ebola-free. However, the role of host factors involved in sexual
transmission remain unknown. We find that seminal amyloids are able to greatly enhance EBOV
infection and alter the virion physical properties, stabilizing viral infectivity and protecting the virus
from drying. These results suggest these seminal amyloids as possible targets for intervention to
prevent EBOV sexual transmission and seeding new infection chains that reignite an outbreak.
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Section 3.3 – Introduction
The 2014-2016 Western Africa Ebola outbreak was the largest Ebola outbreak on record,
causing more than 28,652 cases and killing 11,3251. Ebola virus [EBOV] disease (EVD) is primarily
spread by contact with bodily fluids of an infected individual or a person who has died from EVD.
Even after recovery from EVD, EBOV remains detectable in several anatomic locations and bodily
fluids, including in semen2. Cohort studies of male EVD survivors demonstrated that infectious
EBOV could be isolated from semen up to 82 days after EBOV onset3,4. The maximum recorded
persistence of EBOV RNA in semen is 965 days, although the concordance between persistent
RNA and infectious virus is unclear5. During the 2014-2016 EBOV outbreak, multiple cases of
sexual transmission – some sparking new transmission chains – were reported in case reports
supported by epidemiological and molecular evidence6–10. Transmission was reported from a male
survivor 470 days after his EVD onset9. An epidemiological model of EBOV sexual transmission in
Sierra Leone predicted that if survivors experienced even a 3-month infectious period, the outbreak
would be extended by an average of 83 days11.
EBOV tropism is broad12,13 and histological studies demonstrate a wide variety of cell types
infected in vivo during infection12,14–16. It has been suggested that monocytes, macrophages, and
dendritic cells in particular are important early targets for infection 12,16–19. EBOV entry into cells is
enhanced by interactions between the virion and cellular attachment factors that include C-type
lectins (e.g. DC-SIGN and DC-SIGNR)20–24 and phosphatidylserine-binding molecules such as
Tyro3 family members (e.g. Axl)25 and TIM-126. EBOV requires macropinocytosis as an uptake
mechanism27–29, resulting in its trafficking to acidified endosomes where the glycoprotein is
processed by cathepsin B/L proteases30. After processing, the glycoprotein interacts with its
receptor Niemann-Pick C1 (NPC1) to effect fusion between the viral and endosomal
membranes31-33.
Screening of protein/peptide libraries derived from human semen identified peptides that
dramatically enhance viral infection34. The most well-studied of these is PAP248-286, a highly basic
39-amino acid cleavage product of prostatic acid phosphatase (PAP)35. While having no impact on
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HIV-1 infection as a soluble peptide, PAP248-286 assembles into amyloid fibrils termed semenderived enhancer of viral infection (SEVI) which greatly increase HIV-1 infectivity35. Subsequent
analyses have identified other amyloid fibrils in semen that enhance HIV-1 infection, including
another cleavage product of PAP (PAP85-120)36 and fragments of semenogelin-1 and -2,
components of the seminal coagulum 37. Both positive charge and amyloid character are important
for enhancement of HIV-1 infection by SEVI, as modified peptides without positive residues form
amyloid fibrils with greatly diminished enhancement ability38. Anionic polymers such as dextran
sulfate38 and molecular tweezers that bind positively charged amino acids39 inhibit SEVI’s
enhancement effect, highlighting the importance of charge. Subsequent reports have identified
enhancement roles for these fibrils for infection by SIV, CMV, and HSV-1, though the enhancement
effects were generally lower for these viruses than those reported for HIV-140–42.
A leading model of SEVI enhancement of infection posits that the highly positive charge of
the amyloid fibrils reduces electrostatic repulsion between the negative charges of the virion and
cellular membranes. For HIV-1, an increase in virus attached to the cell surface was detected upon
pretreatment of the virus with SEVI relative to virus alone35. SEVI fibrils are endocytosed by cellular
protrusions, but the role this plays in enhancement of viral infection is not known35. It has also been
reported that fusion of the viral and cellular membranes is enhanced upon pretreatment of HIV-1
with SEVI, though it is unclear whether SEVI enhances fusion per se or if increased
attachment/binding results in an increase in downstream entry events35.
The ability of sexual transmission to reignite an outbreak warrants examination of factors
affecting EBOV sexual transmission. In this study, we addressed whether seminal amyloids
enhanced EBOV infection in vitro. Our results indicate that SEVI and other seminal amyloid fibrils
greatly enhanced infection mediated by the EBOV glycoprotein using both non-pathogenic EBOV
surrogates and authentic EBOV. This enhanced infection retained requirements for EBOV infection
including macropinocytic uptake and cathepsin processing. In addition, we identify a new potential
role for seminal amyloid fibrils in enhancing viral stability after extended incubation at elevated
temperature or upon desiccation.
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Section 3.4 – Materials and Methods
Viruses and cells. Recombinant VSV expressing the EBOV glycoprotein and mCherry (rVSVEboGP-mCherry) has been previously described43,44. To generate rVSV-EboGP-mCherry stocks,
Vero CCL81 cells (gift from Susan Weiss, U. Pennsylvania) were infected at an MOI of 0.001 for 3
days; clarified supernatant was buffered with 25 mM HEPES, aliquoted, frozen at -80°C, and titered
by TCID50 on Vero CCL81 cells. EBOV/“Zaire 1995” (EBOV/H.sap-tc/COD/95/Kik-9510621) was
used in authentic virus studies45. HeLa, A549, and THP1 cell lines and macrophages differentiated
from purified human blood monocytes were used as target cells for infections. 293T cells were used
for transfection. Samples obtained from the University of Pennsylvania Human Immunology Core
are considered to be a secondary use of deidentified human specimens and are exempt via Title
55 Part 46, Subpart A of 46.101 (b) of the Code of Federal Regulations. 293T, HeLa, and A549
cells (ATCC) were maintained in DMEM with 4.5 g/L glucose and no sodium pyruvate
supplemented with 10% FBS (Sigma). THP1 cells were maintained in RPMI-1640 supplemented
with 10% FBS and 50 mM β-mercaptoethanol. Human monocyte-derived macrophages were
maintained in RPMI-1640 with glutamine, 10% FBS, and penicillin/streptomycin, and were
differentiated from peripheral blood monocytes by incubation in 20 μg/mL MCSF (Gemini) for 7
days.

Peptides and Fibrils. SEVI, SEVI-Ala, PAP85-120, SEM1, and SEM2 fibrils were generated by
dissolving peptides (Keck Biotechnology Resource Laboratory, Yale University) in PBS, filtering
through a 0.2 μm filter, seeding with 1% preformed amyloid, and incubating at 37°C with shaking
at 1400 rpm35–37. Amyloid formation was confirmed by assessing thioflavin T fluorescence. Aliquots
were stored at -80°C and working stocks kept at 4°C. Peptide sequences are available in
Supplementary Table 3.1.

Infection assays. rVSV-EboGP-mCherry was diluted into DMEM-10 alone or supplemented with
amyloid fibrils or soluble peptides and incubated at 37°C for 15 minutes. 20 μL of the infection
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mixture was added to each well of target cells in a 96-well plate (plated at 1.5e4 cells/well the
previous day in 100 µL DMEM-10) and incubated at 37°C for 1 h, then the media was replaced with
fresh DMEM-10 and incubated at 37°C for a total of 12 h. Cells infected in the presence of SEVI
were harvested by trypsinization, fixed in 2% paraformaldehyde (PFA), and analyzed by flow
cytometry for mCherry expression. For experiments containing amyloids other than SEVI, the cells
were fixed, permeablized with 0.1% saponin in FACS buffer (1% BSA, 0.01% sodium azide in PBS),
and stained for 1 h with a combination of 1:1000 mouse monoclonal anti-VSV(M) primary antibody
(gift from Robert Doms, U. Pennsylvania) and 1:5000 goat anti-mouse secondary antibody labeled
with AF488 (Life Technologies) before analysis by flow cytometry. For each experiment, the
average of triplicate technical replicates was log-transformed, and transformed percents infection
of biological replicates were compared by repeated measures ANOVA with post hoc analysis using
false discovery rate analysis to correct for multiple comparisons (GraphPad Prism). Monocytederived macrophages were treated with B18R (Abcam) for 24 h prior to as well as during infection
to inhibit the interferon response.

For authentic virus infections, peptides were diluted to 5-50 µg/ml and pre-incubated with EBOV
for 15 minutes. HeLa cells were exposed to peptide/virus inoculum at an MOI of 2.0 or 0.2 PFU/cell
for 1 h, after which peptide/virus inoculum was removed and fresh culture media added. At 24-48
h post-infection, cells were formalin-fixed, removed from containment, and immunostained using
the 13F6 antibody46 at 2 µg/ml. Infection was quantified using automated fluorescence microscopy
as described47.

Binding/Internalization assays. rVSV-EboGP-mCherry was pretreated with or without SEVI then
bound to HeLa cells on ice. Cells were either lysed in 1% Triton for 10 minutes on ice after 1 h
(binding) or warmed to 37°C for 1 h to allow viral internalization, washed 3x in PBS with Ca2+ and
Mg2+, trypsinized for 10 minutes at 37°C, and lysed with 1% Triton for 10 minutes on ice
(internalization). Lysates were separated on a 12% Criterion TGX gel, transferred to nitrocellulose
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for 1 h, and blocked with TBS Odyssey Blocking Buffer (Li-Cor). Membranes were probed for VSV
M (1:1000, Ab as above) and GAPDH (1:2000, rabbit polyclonal, Santa Cruz Biotechnology) in TBS
Blocking Buffer/0.2% Tween simultaneously for 1 h, then with IRDye 800CW goat anti-mouse and
IRDye 680RD goat anti-rabbit (1:15,000, Li-Cor) in TBS blocking buffer/0.2% Tween. Membranes
were then analyzed by quantitative Western blotting by comparing VSV M signal to GAPDH signal
for each sample.
Virus-like particle generation. 293T cells were plated in 15 cm plates the day before transfection.
Cells were transfected with 7.5 μg each of pCAGGS-EboGP, pCAGGS-VP40, and either pCAGGSVP40(luc) or pCAGGS-VP40(GFP) with polyethylenimine48. Supernatants were collected at 24 and
48 h after transfection, concentrated through a 20% sucrose cushion by ultracentrifugation,
resuspended in 1% BSA, 50 mM HEPES-buffered PBS, and frozen at -80°C until use.
VLP binding assay. HeLa cells were plated in a 96-well plate at 1.5e4 cells/well the day before the
assay and incubated on ice for 30 min prior to the experiment. SEVI fibrils were diluted to 35 μg/mL
in DMEM-10 and mixed with 3 μL concentrated EBOV VLP (VP40-luc) and incubated at 37°C for
10 min. 20 μL of the mixture was added to triplicate wells and spun at 1200g for 30 min at 4°C.
After spinning, the cells were washed 5X with cold DMEM-10 and lysed with Bright-Glo luciferase
assay buffer (Promega). Luciferase activity was read on a Luminoskan Ascent (Thermo) 10 minutes
after addition of assay buffer, and after background subtraction, readings were normalized to 0
μg/mL SEVI condition. Statistical significance was determined by paired t-test of log-transformed
data (StataIC 14).
VLP internalization assay. The VLP internalization assay was done similarly to what has been
previously described49. HeLa cells were plated in a 96-well plate at 1.5e4 cells/well the day before
the assay. Cells treated with EIPA were pretreated with 100 μM EIPA for 1 h prior to the beginning
of the experiment and incubated on ice for 30 minutes prior to the beginning of the experiment.
SEVI fibrils were diluted to 35 μg/mL in DMEM-10 and mixed with 2 μL EBOV VLP (VP40-GFP)
and incubated at 37°C for 10 min. After incubation, 20 μL of this mixture was added to triplicate
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wells and spun at 1200g for 30 min at 4°C. The plate was then shifted to 37°C for 1 h. The cells
were then trypsinized, fixed in 2% PFA, and analyzed by flow cytometry for geometric mean
fluorescence intensity in the GFP channel. Statistical significance was determined by repeated
measured ANOVA with false discovery rate correction (GraphPad Prism).
Dextran uptake assay. HeLa cells were plated in a 96-well plate at 1.5e4 cells/well the day before
the assay. Cells treated with EIPA were pretreated with 100 μM EIPA for 1 h. Culture medium was
removed from each well and replaced with indicated concentrations of SEVI diluted in DMEM-10
with or without 100 μM EIPA in triplicate. The cells were incubated at 37°C for 20 minutes, then 2.5
μL of 20 mg/mL FITC-dextran (70 kDa in DMSO, Invitrogen) was added to each well for 10 minutes
at 37°C. Afterward, the medium was removed and replaced with 100 μL of PBS pH 4.9 to bleach
any uninternalized FITC. Cells were trypsinized and fixed in 2% PFA, washed 3X with FACS buffer
(1% BSA in PBS, 0.1% sodium azide) and analyzed by flow cytometry. Data were analyzed with
FlowJo to determine geometric mean fluorescence intensity in the FITC channel. Statistical
significance was assessed by linear regression analysis or repeated measures ANOVA with false
discovery rate correction (GraphPad Prism).
Inhibitor treatments. HeLa cells were plated in a 96-well plate at 1.5e4 cells/well the day before the
assay. Cells treated with inhibitors [100 μM EIPA (Toronto Research Chemicals), 1 μM cytochalasin
D (Cayman Chemical Company), 0.5 μM 17-hydroxywortmannin (Cayman Chemical Company),
50 μM LY294002 (Cayman Chemical Company), 50 mM NH 4Cl (Fisher), 10 μM Z-FF-FMK (EMD
Biosciences), 10 μM leupeptin (Sigma), 10 μM E64 (EMD Biosciences), or 10 μM MDL28170
(Calbiochem)] were pretreated for 1 h before infection. Cells were infected as described earlier.
After 1 h of infection, the virus- and inhibitor-containing medium was removed and replaced with
medium without inhibitor for the remainder of the incubation. Infections were harvested and
analyzed for percent infection as described above. To test for cytotoxic effects, HeLa cells were
treated with inhibitors for 2 h before assessment for viability by the CellTiter 96 AQueous One
Solution Cell Proliferation assay kit (Promega) according to manufacturer instructions.
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Virus stability analysis. rVSV-EboGP-mCherry was diluted from stock concentrations to
concentrations of 1e7 TCID50/mL in artificial semen simulant, with or without SEVI fibrils or αsynuclein fibrils (35 μg/mL). For thermal stability experiments, samples were taken immediately (0
h timepoint) or after indicated times of incubation at 37°C in a thermocycler with heated lid to
minimize evaporation. Samples were frozen at -80°C until titration by TCID50. For desiccation
tolerance experiments, 10 μL of diluted virus in artificial semen simulant was spotted in the bottom
of non-tissue-culture-treated 96-well plates and allowed to dry under laminar flow in a biosafety
cabinet at room temperature for indicated lengths of time. For comparison, samples from the bulk
liquid (maintained at room temperature in sealed tube) were taken at the initial timepoint and the
last timepoint. Samples were immediately titered by TCID50 after addition of 200 μL of DMEM to
recover virus from the dried samples.
TCID50. Vero cells were plated the previous day at 1.5e4 cells/well in 96-well plates. Viral samples
were serially diluted in serum-free DMEM then added in 8-fold replicate to 96-well plates. After 4872 h, wells were scored by presence/absence of viral replication as marked by fluorescent protein
expression and cytopathic effects. TCID50/mL was calculated by the Spearman & Kärber
algorithm50. Data were log-transformed and analyzed for statistical significance by nonlinear
regression (GraphPad Prism).
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Section 3.5 – Results
Section 3.5.1 – Seminal amyloids enhance rVSV-EboGP-mCherry infection
The enhancement ability of seminal amyloids on EBOV glycoprotein-mediated infection
was first assessed with a recombinant vesicular stomatitis virus expressing the EBOV glycoprotein
(rVSV-EboGP-mCherry, Fig 3.1A). Recombinant or pseudotyped VSV systems have been widely
used to explore the interactions of the EBOV glycoprotein and viral membrane with cells during
entry due to faithful mimicry of the EBOV infection process in a BSL-2 environment 30,31,51,52. SEVI
is the best studied of the seminal amyloids, having been the first characterized and having variants
available to explore mechanistic details35,38. Chemically synthesized PAP248-286 peptides were
assembled into SEVI amyloid fibrils and preincubated with rVSV-EboGP-mCherry at indicated
concentrations. These mixtures were used to infect cell lines representing potential target cell types
during EBOV sexual transmission, including epithelium-derived HeLa and A549 cells and
monocyte-derived THP1 cells. Percent infection was measured by flow cytometry for the mCherry
reporter. Preincubation of rVSV-EboGP-mCherry with SEVI resulted in a striking increase in
infectivity by 16.9- to 20.5-fold for the cell lines analyzed at 35 μg/mL, the concentration of SEVI
reported in human semen35 (Fig 3.1B-C). A 4.3-fold increase in output virus was observed in
primary monocyte-derived macrophages, indicating that the enhancement effect was not limited to
cell lines (Fig 3.1D). These experiments were done at low multiplicity of infection, when
enhancement by SEVI has been characterized as most effective 35. However, due to concerns of
reproducibility with such low initial percent infection, most subsequent studies were done at higher
MOI with a concomitant decrease in fold enhancement.
Other amyloidogenic peptides derived from the seminal proteins prostatic acid
phosphatase (PAP85-120), semenogelin-1 (SEM1), and semenogelin-2 (SEM2) have been
reported to enhance viral infection36,37,41. To determine whether these other amyloid fibrils enhance
infection mediated by the EBOV glycoprotein, rVSV-EboGP-mCherry was preincubated with
physiological concentrations of SEVI fibrils, PAP85-120 fibrils, representative SEM1 fibrils, or
representative SEM2 fibrils and used to infect HeLa cells (MOI 3). Because of background for these
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other peptides in the mCherry channel (Fig 3.S1), infection was quantified by flow cytometry after
staining for VSV M protein. We observed that all four amyloid peptides significantly increased
infection by rVSV-EboGP-mCherry, with the SEM1 amyloid fibrils exhibiting the highest fold
increase of 20.3-fold (Fig 3.1E). The SEM2 and PAP85-120 peptides also significantly enhanced
infection by the recombinant virus by 9.2- and 4.2-fold, respectively. These results demonstrate
that rVSV-EboGP-mCherry infection is enhanced, to differing degrees, by four amyloid fibrils
present in human semen.
SEVI-mediated enhancement of infection has been previously found to be dependent upon
the charge and amyloid character of the peptides35,38. To determine whether SEVI-mediated
enhancement of rVSV-EboGP-mCherry maintains similar specific requirements, rVSV-EboGPmCherry was pretreated with SEVI fibrils, SEVI fibrils in which the positively-charged amino acids
have been replaced with alanine (SEVI-Ala)38, or freshly dissolved PAP248-286. HeLa cells were
infected with the virus-peptide mixtures (MOI 3) and infection was analyzed by flow cytometry for
mCherry expression. Unlike SEVI, which effected a 7.5-fold enhancement of rVSV-EboGPmCherry infection at this MOI, infection in the presence of SEVI-Ala or soluble PAP248-286-treated
virus did not differ from rVSV-EboGP-mCherry alone (Fig 3.1F). These results indicate that much
like enhancement of HIV-1 infection, the positive charge and amyloid character of the peptide are
both critical for rVSV-EboGP-mCherry enhancement.
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Figure 3.1. Seminal amyloids enhance rVSV-EboGP-mCherry infection.7
A. Schematic of the genomic organization of rVSV-EboGP-mCherry. B. HeLa, A549, and THP1 cells were infected with rVSV-EboGPmCherry at MOI 1in the presence or absence of SEVI and analyzed for mCherry expression. C. Normalized infection of HeLa, A549,
and THP1 cells infected with rVSV-EboGP-mCherry preincubated with increasing concentrations of SEVI fibrils; n=3, mean ± SEM. D.
Normalized output titer of human monocyte-derived macrophages infected with rVSV-EboGP-mCherry (MOI 3) preincubated with or
without SEVI; n=3, mean ± SEM. E. Normalized infection of HeLa cells infected with rVSV-EboGP-mCherry at MOI 3 with or without 35
μg/mL SEVI fibrils, 39 μg/mL PAP85-120 fibrils, 90 μg/mL SEM1 fibrils, or 90 μg/mL SEM2 fibrils; n=3, mean ± SEM. *p<0.05, **p<0.01
by ANOVA. F. Normalized infection of HeLa cells infected with rVSV-EboGP-mCherry (MOI 3) pretreated with or without 35 μg/mL SEVI
fibrils, SEVI-Ala fibrils, or soluble PAP248-286; n=3, mean ± SEM. **p<0.01 by ANOVA.
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Section 3.5.2 – SEVI enhances EBOV VLP binding and internalization
To characterize the mechanism of SEVI-mediated enhancement of Ebola glycoproteinmediated infection, binding and internalization experiments were performed. To assess impacts on
binding, rVSV-EboGP-mCherry was preincubated with SEVI before binding to HeLa cells on ice for
1 h. Afterward, the cells were lysed on ice. Lysates were analyzed by quantitative Western blotting,
probing for VSV M to assess quantity of virus present using GAPDH as a loading control. Signal in
the presence of SEVI was compared to rVSV-EboGP-mCherry bound in the absence of SEVI. Only
a modest increase in binding (1.5- to 2-fold) that saturated below the concentrations of SEVI tested
was observed (Fig 3.2A). Binding was further quantified with a binding assay using EBOV viruslike particles (VLPs). These particles show filamentous morphology and replicate steps of the
EBOV entry process28,53–55. VLPs with a luciferase reporter were preincubated with SEVI and bound
to HeLa cells at 4°C with centrifugation, then the cells were washed, lysed in luciferase assay
buffer, and luminescence recorded. In agreement with previous results, an approximately 2-fold
increase in binding was observed in the presence of SEVI (Fig 3.S2A).
Internalization by macropinocytosis is essential for EBOV entry, therefore the impact of
SEVI on internalization was also analyzed in a similar way. After binding to cells on ice, the cells
were shifted to 37°C for an additional hour to permit internalization. The cells were then washed
and trypsinized to remove bound but uninternalized virus, then lysed and analyzed by Western
blotting. Strikingly, quantitative Western blotting analysis demonstrated a linear (R2=0.9894) dosedependent relationship between SEVI preincubation concentration and relative internalization, with
physiological concentrations of SEVI resulting in an approximately 10-fold increase in
internalization of rVSV-EboGP-mCherry after background subtraction (Fig 3.2B). To further confirm
this finding, EBOV VLPs labeled with GFP were preincubated with SEVI and bound to HeLa cells
on ice then shifted to 37°C. After trypsinization, cells were analyzed by flow cytometry for GFP
signal. While less quantitative than the blotting analysis, an increase in geometric mean
fluorescence intensity of approximately 25% was observed in the presence of SEVI, suggesting
that cells internalized a significantly higher quantity of VLPs when pretreated with SEVI than without
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pretreatment (Fig 3.S2B). This effect was ablated by the macropinocytosis inhibitor N-(ethyl-Nisopropyl)-amiloride (EIPA), suggesting efficient removal of bound VLPs from the cell surface.
The ability of SEVI to enhance viral internalization has not been previously reported.
Previous reports have shown that SEVI is internalized into cells, raising the possibility it may induce
endocytosis35. To explore the ability of SEVI to modulate macropinocytosis in a virus-free
environment, HeLa cells were incubated at 37°C with different concentrations of SEVI for 20
minutes before the addition of a macropinocytic marker molecule FITC-dextran for 10 minutes. The
cells were treated with PBS pH 4.9 to bleach any uninternalized FITC and trypsinized, and then
geometric mean fluorescence intensity (gMFI) was determined by flow cytometry. A linear
relationship (R2 = 0.9799) was observed between SEVI concentration and gMFI, with the highest
concentrations of SEVI leading to a 3.7-fold increase in macropinocytic uptake (Fig 3.2C). This
increase in fluorescent intensity was ablated in the presence of EIPA, indicating efficient bleaching
of bound FITC signal and a specificity of macropinocytosis for uptake (Fig 3.2C). The enhanced
FITC-dextran internalization depended upon the charge and amyloid character of the SEVI peptide,
as SEVI-Ala and soluble PAP248-286 peptide treatment showed no increase in dextran uptake
(Fig 3.2D). These results provide evidence for the ability of SEVI to promote macropinocytic uptake
to increase internalization of EBOV particles.
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Figure 3.2. SEVI enhances rVSV-EboGP-mCherry binding, internalization, and cellular
macropinocytosis. 8
A. HeLa cells were prechilled and treated with rVSV-EboGP-mCherry pretreated with or without
SEVI fibrils. Cells were lysed and the ratio of VSV M:GAPDH signal was compared to untreated
control by quantitative Western blotting; n=3, mean ± SEM. B. HeLa cells were prechilled and
treated with rVSV-EboGP-mCherry pretreated with or without SEVI fibrils. After 1 h, the cells were
shifted to 37°C to allow internalization. Cells were washed, trypsinized, and lysed, and the ratio
of VSV M:GAPDH signal was compared to untreated control by quantitative Western blotting;
n=3, mean ± SEM. C. HeLa cells were treated with different concentrations of SEVI fibrils then
treated with dextran-FITC in the presence or absence of EIPA. Geometric mean fluorescent
intensity was measured by flow cytometry and normalized; n=3, mean ± SEM. **p<0.01 by linear
regression analysis. D. HeLa cells were treated with or without 35 μg/mL SEVI fibrils, SEVI-Ala
fibrils, or soluble PAP248-286 then 70 kDa dextran-FITC. n=3, mean ± SEM. **p≤0.01 by ANOVA
of gMFI values. E. Normalized percents infection of HeLa cells pretreated with macropinocytosis
inhibitors and infected with rVSV-EboGP-mCherry (MOI 5) with or without 35 μg/mL SEVI fibrils.
F. Normalized percents infection of HeLa cells pretreated with DMEM-10 alone or supplemented
with cathepsin inhibitors infected with rVSV-EboGP-mCherry (MOI 5) pretreated with or without
35 μg/mL SEVI fibrils. For both E and F: n=3, mean ± SEM, *p<0.05, **p<0.01, ***p<0.001 by
two-factor repeated measures ANOVA.
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Section 3.5.3 – SEVI-mediated enhancement maintains EBOV entry requirements
Following binding of the virus to the cell, EBOV particles are endocytosed by
macropinocytosis and traffic through the endosomal system where cellular cathepsins process the
glycoprotein, enabling an interaction of the glycoprotein with its receptor to initiate fusion of the viral
and cellular membranes and infection56. To determine whether the fibril-enhanced infection
diverges from the canonical EBOV entry pathway, cells were infected with rVSV-EboGP-mCherry
in the presence or absence of inhibitors of macropinocytosis or cathepsin activity, with or without
preincubation of the virus with SEVI. No cytotoxic effects were observed with any of these inhibitors
(Fig 3.S3). To inhibit macropinocytosis, HeLa cells were treated with EIPA, cytochalasin D, 17βhydroxywortmannin, or LY294002 for 1 h before and 1 h during infection with the virus-peptide
mixture (MOI 5). While infection by rVSV-EboGP-mCherry was enhanced by SEVI in this
experiment in the absence of inhibitor, all macropinocytosis inhibitors equally reduced infection by
5- to 10-fold in both the absence and presence of SEVI. These results indicate that macropinocytic
entry is not bypassed in the presence of SEVI and that infection maintains this cellular requirement
for EBOV glycoprotein-dependent infection (Fig 3.2E). Similarly, inhibitors of cathepsin activity,
including ammonium chloride, E64, Z-FF-FMK, leupeptin, and MDL28170, abrogated infection of
HeLa cells by 10- to 20-fold in both the presence and absence of physiological levels of SEVI (Fig
3.2F). These results imply that while SEVI enhances infection, it does not permit the virus to bypass
critical cellular requirements for rVSV-EboGP-mCherry entry.

Section 3.5.4 – SEVI alters rVSV-EboGP-mCherry physical characteristics
We next hypothesized that seminal amyloid fibrils could affect the physical characteristics
of the virus, which may impact transmissibility. To determine if the interaction of viral particles with
amyloid fibrils alters the physical characteristics of the virus, we analyzed the effects of thermal and
chemical stressors on viral infectivity. Whether SEVI pretreatment impacts rVSV-EboGP-mCherry
stability over time was assessed by incubation of rVSV-EboGP-mCherry with or without physiologic
SEVI concentrations in artificial semen simulant57 for various lengths of time at 37°C. Artificial
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semen simulant is designed to mimic the chemical composition of semen and contains 5 mg/mL
BSA, making any nonspecific effects of additional protein (e.g. amyloids or peptides) unlikely. At
each timepoint, the titer of virus was determined by TCID50 on Vero cells. Values were normalized
to the starting titer for each condition, log-transformed, and analyzed by nonlinear regression.
Strikingly, the presence of SEVI promoted increased viral viability relative to virus alone (p=0.0029).
The normalized titer of virus incubated in the presence of SEVI was approximately 17-fold higher
than that of virus incubated in semen simulant alone after 36 h (Fig 3.3A). This enhancement in
stability required the positive charge and amyloid character of SEVI, as SEVI-Ala and PAP248-286
had no effect on stability (Fig 3.3A). Further, addition of SEVI immediately before titration after
incubation without SEVI was unable to rescue the effect, suggesting that SEVI exerts its stabilizing
effects during the incubation itself and independently from its infection enhancement ability (Fig
3.3A, 0 μg/mL SEVI+35 μg/mL SEVI). To test whether SEVI promoted resistance to oxidative
stress, we analyzed the ability of rVSV-EboGP-mCherry to resist exposure to dilute concentrations
of chlorine bleach for one minute. Unlike the results found with viral infectivity during prolonged
incubation, SEVI did not enhance the ability of rVSV-EboGP-mCherry to withstand oxidative stress
by chlorine bleach, with equivalent decreases in titer observed both in the presence and absence
of SEVI (Fig 3.S4).
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Figure 3.3. SEVI alters rVSV-EboGP-mCherry physical characteristics.9
A. rVSV-EboGP-mCherry was incubated at 37°C in artificial semen simulant with or without 35
μg/mL SEVI fibrils, SEVI-Ala fibrils, or PAP248-286 peptide and titered by TCID50 on Vero cells.
For the 0 μg/mL+35 μg/mL SEVI condition, SEVI was added immediately before titration after
incubation without. Data were normalized to the 0 h timepoint independently for the conditions
with or without SEVI and fit to one-step decay model; n=3, mean ± SEM. B. rVSV-EboGPmCherry was diluted in artificial semen simulant with or without 35 µg/mL SEVI fibrils and dried
under laminar flow before rehydration and titration by TCID50 on Vero cells. Data were normalized
to the 0 h timepoint independently for the conditions with or without SEVI and fit to plateau
followed by one-step decay model; n=3, mean ± SEM.
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Lastly, we assessed whether the presence of SEVI fibrils could improve desiccation
tolerance; as enveloped viruses, EBOV and rVSV-EboGP-mCherry are sensitive to drying. rVSVEboGP-mCherry was diluted in artificial semen simulant in the presence or absence of
physiological concentrations of SEVI. Samples were maintained in bulk liquid or spotted into 96well plates (10 μL) and allowed to air dry. Samples were taken immediately (0 h) or after varying
lengths of time drying under laminar flow at room temperature. Dried samples were rehydrated with
200 μL of DMEM and infectivity was quantified by TCID 50. Samples were also taken at 6 h from
bulk liquid kept within a sealed tube to assess independently any effects of incubation at room
temperature. TCID50/mL measurements were normalized to the initial timepoint for each and fitted
to a plateau-one phase decay model, which reflects the lag in viral decay until after the liquid has
evaporated. After 6 h of incubation, the normalized titer of virus desiccated in the presence of SEVI
was approximately 10-fold lower than in its absence (Fig 3.3B). Notably, over this timescale at room
temperature, there was no relative difference in viral titer between virus incubated in the presence
or absence of SEVI in bulk liquid (p=0.10), suggesting the observed effects are actually due to
desiccation and not temperature-induced decay (Fig 3.S5). Again, addition of SEVI immediately
before titration after desiccation in its absence had no effect on desiccation kinetics (Fig 3.3B, 0
μg/mL SEVI+35 μg/mL SEVI). This result indicates that SEVI promotes viral viability after
desiccation and rehydration. To better understand the mechanism of SEVI-mediated desiccation
tolerance, rVSV-EboGP-mCherry was also incubated with SEVI-Ala and PAP248-286. While
PAP248-286 had no effect on desiccation tolerance, SEVI-Ala unexpectedly increased viral stability
to the same extent as SEVI under these conditions. To determine if the presence of any amyloid
could give this effect, rVSV-EboGP-mCherry was dried for 6 h in the presence of an equivalent
mass of α-synuclein fibrils, which play a role in Parkinson’s disease pathogenesis58. No stabilizing
effect was seen over incubation in semen simulant alone, suggesting that not all amyloids have
this property (Fig 3.S6). Overall, these results indicate a previously unreported ability of seminal
amyloid fibrils to stabilize viral infectivity, even after incubation at elevated temperatures over time
or desiccation.
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Section 3.5.5 – Seminal amyloids enhance infection by authentic EBOV
To confirm that the SEVI enhancement of rVSV-EboGP-mCherry faithfully mimics infection
by authentic EBOV, HeLa cells were infected with EBOV after preincubation with various
concentrations of SEVI fibrils. Preincubation of EBOV with SEVI led to a dose-dependent
enhancement of infection similar to that observed with rVSV-EBOV-mCherry, resulting in a 28.9fold increase in infection after 24 h at the physiologic concentration of SEVI (MOI 0.2) (Fig 3.4A).
As with EboGP-mediated VSV infection, the EBOV infection enhancement was dependent upon
the charge and amyloid nature of the fibrils. In contrast to a 22.8-fold increase in infection observed
in the presence of SEVI fibrils in this experiment, EBOV infection (MOI 2) was not enhanced by
SEVI-Ala fibrils or soluble PAP248-286 (Fig 3.4B). Preincubation of EBOV with the other seminal
peptides also enhanced infection at 24 h by 37.2-fold for PAP85-120 fibrils, 34.3-fold for SEM1
fibrils, and 41.3-fold for SEM2 fibrils (all 35 μg/mL, MOI 2), in agreement with the results observed
for rVSV-EBOV-mCherry (Fig 3.4C, 3.1E).
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Figure 3.4. Seminal amyloids enhance EBOV infection. 10
A. Normalized infection of HeLa cells infected with EBOV (MOI 0.2) preincubated with increasing
concentrations of SEVI fibrils; n=2, mean ± SEM. B. Normalized infection of HeLa cells infected
with EBOV (MOI 2) pretreated with or without 35 μg/mL SEVI fibrils, SEVI-Ala fibrils, or soluble
PAP248-286; n=2, mean ± SEM. C. Normalized infection of HeLa cells infected with EBOV (MOI
2) pretreated with or without 35 μg/mL SEVI fibrils, PAP85-120 fibrils, SEM1 fibrils, or SEM2 fibrils;
n=2, mean ± SEM.
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Section 3.6 – Discussion
Reports of EBOV sexual transmission during the West Africa Ebola epidemic, though rare,
are backed by strong epidemiological and/or molecular evidence6–10. Male-to-female transmission
of persistent virus has been linked to resurgence of EBOV, but factors potentially involved in EBOV
sexual transmission have not been characterized. This report provides evidence that seminal
amyloid fibrils, a ubiquitous component of semen in healthy individuals, enhance in vitro infection
by both an EBOV surrogate system and authentic EBOV. These fibrils act in a conformation- and
charge-dependent manner to increase infection by increasing virion binding to host cells and
enhancing macropinocytotic uptake. Further, we find that these fibrils act to protect virions from
stresses potentially encountered during transmission, including thermal degradation and
desiccation.
Ebola sexual transmission presented a significant and novel public health problem during
and following the West Africa Ebola epidemic. Though rare and likely mitigated by public health
agencies’ safe sex education initiatives, it has become apparent that semen of individuals with
persistent EBOV is a potentially important vehicle to consider for EBOV transmission. For a
successful male-to-female sexual transmission event, EBOV present in semen must either infect
or cross the vaginal epithelium. Recent studies demonstrate that EBOV is able to infect the vaginal
epithelium in guinea pig models59. Notably, the amount of infectious virus in semen has been
difficult to determine, but at late time points is likely much lower than that in bodily fluids during
acute illness. Prior studies on HIV indicate that the enhancement effect of SEVI is greatest with
very low viral inoculums35; therefore, the effect of SEVI may be disproportionately important in
EBOV sexual transmission as seminal viral titers wane. Animal models have suggested that
macrophages and dendritic cells are early targets of the virus 12,16–19. Our results indicate that
seminal amyloids enhance infection of epithelial and monocytic cells and subsequent viral
replication and thus could impact early events in sexual transmission. These cells express
numerous attachment factors that increase the efficiency of infection by EBOV, including DC-SIGN.
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Whether SEVI permits EBOV to bypass this dependence upon attachment factors or synergistically
enhances attachment is not known and worth further study.
In addition, our results demonstrate that amyloids impart resistance of the virus to
potentially relevant environmental stresses, including extended incubations at physiological
temperatures and desiccation. The ability of environmental factors to affect virion properties and
infectivity is seen in other systems. As an example, recent studies have found that bacterial
lipopolysaccharide (LPS) induces a conformational change in the poliovirus capsid, increasing virus
binding to its cellular receptor and enhancing the stability of the virion60. These findings are similar
to those we now report regarding the interaction of an enveloped virus and seminal amyloid fibrils.
After binding to SEVI, rVSV-EboGP-mCherry binding, internalization, and tolerance to
environmental stresses increase. The mechanism for this enhanced environmental resistance is
unclear, but could involve retention of water molecules by the large amyloid fibrils to create a
microenvironment surrounding the virions that is relatively resistant to changes in the larger-scale
environment. The exact characteristics necessary for desiccation tolerance are unclear given the
unexpected ability of SEVI and SEVI-Ala to enhance tolerance while another amyloid did not.
Future experiments may involve exploration of the enhancement properties of a wider array of
amyloids, as well as testing other viruses such as HIV-1. Resistance to environmental factors may
be important to consider when assessing the ability of semen to remain infective over time.
Moreover, the seminal amyloids may represent prophylactic drug targets, as strategies to
disassemble the amyloids have been investigated34.
Since the identification of seminal amyloid fibrils as enhancers of HIV-1 infection in 2007,
infection by several viruses with sexual transmission routes have been found to also be enhanced
by SEVI. While not all sexually transmitted viruses are enhanced – notably, Zika virus is not
enhanced appreciably by SEVI despite reports of Zika virus sexual transmission, potentially
because of the dense Zika virus glycoprotein structure (Fig 4.1) – enhancement of infection by
these viruses may represent a common target for intervention. Mechanistically, enhancement by
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Figure 3.5. Model of SEVI-mediated enhancement of EBOV infection.11
seminal amyloids has been proposed to enhance binding of the virus to the cell by alleviating
repulsive interactions between the viral and cell membranes. Our results suggest that its effect on
binding is modest, but SEVI stimulates macropinocytosis to increase viral internalization in addition
to changing the physical properties of the virion (Fig 3.5). The enhancement of infection of primary
monocyte-derived macrophages, as well as the striking increases in macropinocytosis observed in
this study, are reminiscent of a recent report in which clearance of sperm cells by macrophages is
enhanced by seminal amyloids61. Parallels between the clearance of spermatocytes by
macrophages stimulated to engulf the cells by phagocytosis, and internalization of EBOV by
phagocytic cells via a similar uptake mechanism are particularly intriguing.
An important limitation of the present study is the inability to study this phenomenon in an
in vivo model, as no model for EBOV sexual transmission of persistent virus exists, and the
challenges associated with developing one are considerable. However, seminal fibrils may
represent an intriguing prophylactic target since agents that affect fibril stability or formation may
target increased infectivity at a cellular level as well as enhanced viral stability ex vivo. Altogether,
these findings represent the first analysis of molecular factors potentially involved in EBOV sexual
transmission and may promote further study of this novel transmission route of an important human
pathogen.
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Section 3.8 – Supplemental Information

Supplementary Table 3.1. Peptide Sequences
SEVI
SEVI-Ala
PAP85-120
SEM1 (45–107)
SEM2 (49-107)

GIHKQKEKSRLQGGVLVNEILNHMKRATQIPSYKKLIMY
GIHAQAEASALQGGVLVNEILNHMAAATQIPSYAALIMY
IRKRYRKFLNESYKHEQVYIRSTDVDRTLMSAMTNL
GQHYSGQKGKQQTESKGSFSIQYTYHVDANDHDQSRKSQQYDLNALHKTTKSQRHLGGSQQLL
GQKDQQHTKSKGSFSIQHTYHVDINDHDWTRKSQQYDLNALHKATKSKQHLGGSQQLL
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Figure 3.S1. SEM1 and PAP85-120 exhibit autofluorescence in the mCherry channel. 13
HeLa cells were treated with seminal amyloids and autofluorescence was measured by flow
cytometry. The percentage of cells in the 610_20 Green gate indicates background
autofluorescence.

S2A

S2B

Figure 3.S2. SEVI enhances VLP binding and internalization. 12
A. HeLa cells were prechilled and treated with EBOV VLPs (VP40-luc) pretreated with or without
35 μg/mL SEVI fibrils. After spinfection, cell-associated luciferase signal was determined and
normalized; n=3, mean ± SEM. **p<0.01 by paired t test. B. HeLa cells were prechilled and treated
with EBOV VLPs (VP40-GFP) pretreated with or without 35 μg/mL SEVI fibrils. After allowing
internalization, cells were analyzed for geometric mean fluorescence intensity of GFP. *p<0.05,
***p<0.001 by repeated measures ANOVA.
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Figure 3.S3. Macropinocytosis and cathepsin inhibitors do not exhibit cytotoxicity. 14
HeLa cells were treated for 2 h with inhibitors in concentrations as described in Materials and
Methods then cell viability was assessed by the CellTiter 96 AQueous One Solution Cell
Proliferation assay. n=2, mean±SD.

Figure 3.S4. SEVI does not promote increased stability following treatment with dilute bleach
rVSV-EboGP-mCherry was diluted in DMEM-10 alone or supplemented with 35 μg/mL SEVI
fibrils and treated with PBS or chlorine bleach diluted in PBS for a final concentration of 0.005%
hypochlorite for 1 minute. The samples were then neutralized with sodium thiosulfate (10-fold
excess of 0.01% solution) and titered by TCID50 on Vero cells. n=1, mean±SD.
15
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Figure 3.S5. No differential thermal degradation occurs over six hours at room temperature in the
presence or absence of SEVI.17
rVSV-EboGP-mCherry was diluted in artificial semen simulant alone or supplemented with 35
µg/mL SEVI fibrils and titered either immediately or after six hours of incubation in a sealed tube at
room temperature by TCID50 on Vero cells. p=0.10 by paired t test.

Figure 3.S6. α-synuclein does not enhance rVSV-EboGP-mCherry desiccation tolerance.16
rVSV-EboGP-mCherry was incubated at 37°C in artificial semen simulant with or without 35 μg/mL
SEVI fibrils and titered by TCID50 on Vero cells. n=1.
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS
Section 4.1 – Summary
Sexual transmission of persistent EBOV during the unprecedented 2014 Ebola epidemic
represents an avenue by which outbreak control can be compromised. Despite the major public
health problem that this presents, very little is known about the mechanisms involved in EBOV
sexual transmission. This work is the first to study the role of host factors involved in EBOV sexual
transmission at a molecular level.
Seminal amyloids, typified by SEVI, have been shown to greatly enhance the ability of
HIV-1 and other viruses to infect cells in vitro. This work demonstrates that SEVI and other seminal
amyloids are able to greatly enhance infection not only by a recombinant virus vector bearing the
EBOV glycoprotein, but also by authentic EBOV in experiments conducted under Biosafety Level
4 conditions. This enhancement occurs in multiple cell types, including epithelium-derived cell lines,
a monocyte-derived cell line, and primary monocyte-derived macrophages.
At a molecular level, SEVI appears to enhance infection by rVSV-EboGP-mCherry by
enhancement of entry. Similar to effects on other viruses including HIV-1, SEVI induces a modest
increase in binding of the virus to the cell. However, this work shows a novel function of SEVI to
greatly increase internalization of the virus into the cell. SEVI accomplishes this function by
enhancing macropinocytosis in a dose-dependent manner. After the virus is internalized by this
critical pathway, it appears to follow the typical EBOV entry process and maintains requirements
for cathepsin processing of its glycoprotein.
This work demonstrates further novel functions for SEVI in viral stability. As an enveloped
virus, EBOV (and the recombinant VSV) are sensitive to prolonged incubations at physiologic
temperature as well as desiccation. Incubation of virus with SEVI instills additional stability in both
situations, suggesting that seminal amyloid fibrils may increase viral infectivity under adverse
environmental conditions.
The mechanistic details for SEVI-mediated enhancement of infection and stability were
also explored. Much like the results observed for HIV-1 enhancement, enhancement of rVSV-
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EboGP-mCherry and EBOV infection required that SEVI maintain its positive charge as well as its
amyloid character. Uncharged and soluble forms of SEVI were unable to increase macropinocytic
uptake in cells. Similarly, only SEVI fibrils were able to enhance stability at physiologic temperature,
with uncharged and unpolymerized forms showing no benefit over virus alone. In contrast, fibrils
with positive residues replaced by alanine were able to instill protection from desiccation to the
same degree as wild type SEVI fibrils, while soluble peptide had no effect.
Altogether, these findings indicate that amyloid fibrils are potentially able to enhance EBOV
by two distinct mechanisms. At a molecular level, SEVI enhances infection by increasing binding
and internalization. In an environmental context, SEVI enhances the ability of the virus to withstand
environmental stresses, which may permit increased transmissibility.
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Section 4.2 – Future directions
The identification of seminal amyloids as a pro-viral component of semen presents
numerous avenues for future research. While this work has given insight into some mechanistic
details regarding the SEVI-EBOV interaction, further study would elucidate a number of factors that
remain unclear.
Section 4.2.1 – Ex vivo infections
The first and perhaps most straightforward next step would be to determine if amyloid fibrils
endogenously present in semen enhance infection and stability of rVSV-EboGP-mCherry.
Protocols for infection as well as for removing seminal amyloids from seminal plasma exist 1,2. Thus,
the ability of semen to enhance infection and stability can be compared to semen devoid of amyloid
fibrils. Collaborating with the Penn Medicine Division of Reproductive Endocrinology and Infertility
for seminal samples, preliminary results suggest that semen does in fact enhance rVSV-EboGPmCherry infection. To further explore the enhancement effect in a model that may better reflect
EBOV sexual transmission, vaginal explant models can be infected with either rVSV-EboGPmCherry or EBOV in the presence and absence of SEVI. The microenvironment in tissue may be
significantly different from that in a culture plate, especially given the diversity of cells in tissue
compared to clonal cell lines. These studies may give insight into the ability of seminal amyloids to
enhance infection of a specific subset of cells, which would perhaps mirror the results of
experimental animal infections that showed early and sustained infection of cells including DCs and
macrophages. Alternatively, the enhanced infection seen in epithelium-derived cell lines lends
credence to a hypothesis that the virus may be able to replicate in vaginal epithelial cells that form
a barrier, establish local infection, then spread to other cell types. Notably, vaginal epithelial cells
are infected in an acute EBOV model in guinea pigs3. No experiments have been done with explant
models and no animal EBOV sexual transmission models exist, leaving the expected results for
these experiments up for conjecture.
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Section 4.2.2 – Enhancement in the context of other viruses
While infection by numerous sexually transmitted viruses is enhanced by SEVI, it does not
appear to be universal. Zika virus (ZIKV), which was responsible for a pandemic across the
Americas marked by an uptick in birth defects including microcephaly, has been demonstrated to
be transmitted sexually in addition to its much more common mosquito transmission route. ZIKV
MR766 (Figure 4.1) and ZIKV Mex 2-81 (data not shown) infection do not appear to be enhanced
by SEVI nearly to the same degree as rVSV-EboGP-mCherry, EBOV, or HIV-1. Because the
mechanism of SEVI-mediated enhancement is hypothesized to be glycoprotein-independent, this
result would seem to be contrary to current models. However, cryo-electron microscopy has been
used to generate models of ZIKV virions that show very little plasma membrane area not occluded
by the E glycoprotein4. Other viruses (including EBOV) have a lower density of glycoprotein on the
virion surface; HIV-1 in particular is notable for its very low density of glycoprotein, with as few as
7-14 spikes being present per virion5–7. Thus, enhancement may not occur with ZIKV due to the
inability of amyloid fibrils to effectively contact the virion membrane. It is unclear, and would be
worth testing, whether ZIKV would exhibit increased stability and desiccation tolerance as does
rVSV-EboGP-mCherry since infection is not enhanced. The ability of SEVI-Ala to promote
desiccation tolerance (Fig 3.3B)
suggests that an electrostatic
interaction may not be required. It
would

also

be

interesting

to

assess whether SEVI enhances
stability of other viruses whose
infection is enhanced by the fibrils,
especially HIV-1. Comparing the
Figure 4.1. SEVI does not dramatically increase ZIKV
infection.18
ZIKV was incubated with SEVI at different concentrations for
to the mechanism of action of the
15 minutes before infection of A549 cells. Infection was
quantified by immunostaining and flow cytometry. n=1.
fibrils for stability promotion.
effects on stability may give clues
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Section 4.2.3 – Stabilization against other environmental factors
The ability of SEVI to promote resistance to some forms of environmental stress raises the
possibility that it may enhance resistance to others. Semen contains proteases and antibodies that
may inhibit viral infection. It is possible that amyloids could bind to viral particles and physically
occlude proteases and antibodies from respectively cleaving or neutralizing the virus. To test the
hypothesis that SEVI could protect virus from proteolysis, rVSV-EboGP-mCherry was treated with
tryspin or proteinase K for 30 minutes at 37°C with the intention of determining whether SEVI would
reduce the sensitivity of the virus to proteolytic inactivation. However, under the conditions tested,
no loss in infectivity was observed after protease treatment. It is unclear whether EboGP is sensitive
to digestion by these enzymes. To more directly test the hypothesis, protocols assessing seminal
protease activity could be adapted for use in a viral setting8.
SEVI has been previously described to reduce the sensitivity of cytomegalovirus (CMV) to
neutralizing antibodies, though extensive characterization of the effect was not completed 9. To
assess whether SEVI impacts neutralization sensitivity of EboGP, rVSV-EboGP-mCherry was
incubated with two different neutralizing anti-EboGP antibodies with or without SEVI for 1 h at 37°C
then used to infect cells. Normalized infection values were used to calculate IC 50 values in the
presence and absence of SEVI (Figure 4.2). There was no difference between IC 50 values in the
presence or absence of SEVI, suggesting no protective effect. It is unclear what difference there is
between the CMV and rVSV-EboGP-mCherry results except that the EboGP neutralization
capacity was tested at numerous concentrations, while the CMV data were a single point and may
not have been representative. It is also possible that the CMV glycoprotein targeted (gH) interacts
with SEVI in some way that renders it less sensitive to neutralization. Studies testing a wider array
of anti-gH antibodies targeting different domains of the glycoprotein could help to clarify the ability
of SEVI to enhance neutralization sensitivity. Further, both anti-EboGP antibodies targeted the
base region of the glycoprotein, and a wider panel of antibodies could assess specific changes in
neutralization sensitivity at other sites.
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Figure 4.2. SEVI does not reduce neutralization sensitivity to anti-EboGP antibodies.19
rVSV-EboGP-mCherry was pretreated or not with SEVI and incubated with different concentrations
of anti-EboGP neutralizing antibody for 30 min at 37°C, then used to infect Vero cells. Infection was
quantified by flow cytometry. n=1.
The finding that both SEVI and SEVI-Ala enhance desiccation tolerance was unexpected.
This finding supports a hypothesis that this stabilization effect occurs through a different
mechanism than enhancement of infection or stability at physiological temperature. It may be that
the large fibrillar structure is able to retain water, creating a local microenvironment in which the
virion is protected from desiccation. The exact requirements for this effect remain unclear, as
incubation with the amyloid α-synuclein had no effect on desiccation tolerance. To better define the
mechanism, future studies could test desiccation tolerance in the presence of a panel of amyloid
fiibrils to determine if this effect is specific to SEVI (and related peptides containing the same
amyloidogenic domains, like SEVI-Ala). Specifically, the other seminal amyloids as well as their
uncharged variants could be used to better understand this phenomenon. Lastly, several species
of bacteria including E. coli have been identified to form extracellular amyloid fibrils using curli
proteins10. Given that EVD is primarily a diarrheal disease, it would be highly clinically relevant if
amyloid secretions by gut bacteria enhance either infection or environmental stability of EBOV.
This could be tested by incubating rVSV-EboGP-mCherry with purified curli then testing for
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enhancement of infection and of stability enhancement. The finding that microbiota could play a
role in EBOV transmission would be novel.

Section 4.2.4 – Mechanisms of enhancement at the cellular and molecular level
It is unclear how SEVI-mediated enhancement interacts with cellular attachment factors.
Expression of attachment factors including DC-SIGN on the surface of cells increases their
susceptibility to infection by EBOV and EboGP-expressing particles. It is unknown how
enhancement of binding and especially internalization by SEVI is modulated by the presence of
these attachment factors. It is possible that seminal amyloids and cellular attachment factors could
synergize to result in an even greater increase in infection, or the presence of seminal amyloids
could physically occlude binding sites on the virion to antagonize the effects of attachment factors.
To assess these possibilities, HEK-293 cells that have a DC-SIGN gene under expression of a
doxycycline-inducible promoter were infected in the presence or absence of physiologic levels of
SEVI, in the presence or absence of doxycycline. No additional increases in rVSV-EboGP-mCherry
infection were seen when SEVI was added to infection of cells expressing DC-SIGN by
fluorescence microscopy, and quantification was not performed. However, for this experiment
relatively high concentrations of SEVI (35 μg/mL) and doxycycline (2 μg/mL) were used, and each
condition alone greatly increased infection. Each factor alone may enhance the entry process of
rVSV-EboGP-mCherry to biologically maximal levels. To address this concern, future experiments
are planned in which lower levels of SEVI (10 μg/mL) and doxycycline (0.2 μg/ml) are used in order
to see any potential synergistic effects. These preliminary results do not support a model of
antagonism between the fibrils and cellular attachment factors, at least as far as attachment factors
that bind EboGP are concerned. PS-binding attachment factors may be more sensitive to occlusion
of membrane phospholipids, and this can be tested in a similar fashion.
The enhancement of EBOV entry via increased macropinocytic uptake is an important new
finding of this work, but the mechanism by which SEVI induces macropinocytosis is unknown. It is
likely that the large, positively charged fibrils will engage multiple cell surface receptors in a

77

nonspecific manner to induce uptake. Macropinocytosis requires activation of Rho GTPases which
regulate actin polymerization that forms membrane ruffles11,12. A number of kinases are also
activated depending upon the upstream signal. Interestingly, while both antibody-dependent
enhancement

(ADE)

of

EBOV

infection

and

antibody-independent

infection

require

macropinocytosis as an entry mechanism, distinct intracellular signaling pathways are activated.
While inhibition of the non-receptor tyrosine kinases Src and Syk have little impact on infection by
rVSV-EboGP pseudotypes, antibody-enhanced infection is blocked in their presence13. These
results indicate that internalization signals downstream of the Fc receptor are distinct from those
normally activated during rVSV-EboGP pseudotype entry. To determine whether a similar disparity
exists during SEVI-enhanced rVSV-EboGP-mCherry infection, HeLa cells were pretreated for 1 h
with the Src inhibitor PP2 then infected with rVSV-EboGP-mCherry. Qualitative observation by
fluorescence microscopy showed no differences in infection between treated and untreated
samples in the presence or absence of SEVI (data not shown). These data do not support the
hypothesis that SEVI-enhanced infection specifically requires a Src-dependent uptake mechanism
and thus is dissimilar to Fc-mediated uptake of rVSV-EboGP. Further candidates, however, could
be tested in the same way to determine if there is differential activation of intracellular signaling
molecules during SEVI enhancement.
It is notable that sexual transmission of EBOV had not been previously described before
the 2014 outbreak. While it is possible that EBOV sexual transmission is simply a rare event that
has not occurred before this outbreak, it is also possible that mutations that arose during the
outbreak contributed to sexual transmission. As previously described, the A82V mutation in EboGP
became prominent during the outbreak 14. This mutation results in an increase in particle infectivity
but detracts from glycoprotein stability during incubations at physiological temperatures 15. Notably,
published sequences of sexually transmitted EBOV contain the V82 allele, though correlations are
difficult to draw due to the small number of sequences available 16. This work describes a novel
function of SEVI to enhance viral stability under those same conditions. It is possible that SEVI
increases stability of the virion to mitigate this decrease in stability. This would result in viral stability
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being perhaps unchanged while the particle is more infective during the transmission event. To test
this hypothesis, the rVSV-EboGP-mCherry vector is being mutagenized to replace the ancestral
A82 allele with V82. After rescue of infectious virus by previously described mechanisms, the A82
and V82 viruses will be compared in their relative stabilities in the presence and absence of SEVI.
If the stability of the V82 virus increases disproportionately in the presence of SEVI, this would
provide support to a hypothesis that this interaction may be important for sexual transmission.

Section 4.2.5 – Implications for antiviral development
The identification of a pro-viral component of semen presents an exciting opportunity for
the development of antivirals that can target the interaction. In this manner, both the molecular
enhancement mechanism as well as the enhancement of environmental stability could be
ameliorated. There has been significant interest in developing compounds that disassemble
amyloid fibrils, both in the context of SEVI and otherwise. Recently, it has been demonstrated that
CLR01, a molecule designed to mask the positive charge of amyloids but that was subsequently
found to disrupt viral membranes, has activity against EBOV pseudoviruses 17,18. It will be interesting
to see the extent to which existing anti-amyloid compounds affect whether these compounds have
effects on the environmental stabilization properties of SEVI in addition to its infectionenhancement activity. In particular, the finding that SEVI-Ala enhances desiccation tolerance may
require development of broader-acting anti-amyloid agents. While SEVI-Ala is not naturally
occurring and thus not per se a concern, its activity raises the possibility that other amyloids or
aggregates may demonstrate similar actions that should also be targeted for maximal impact.
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Section 4.3 – Concluding remarks
In conclusion, this work identifies for the first time that EBOV infection can be enhanced by
amyloid fibrils present in human semen. These fibrils act to enhance infection at a molecular level
by increasing particle binding and internalization by increasing macropinocytosis in target cells.
Further, a novel function of SEVI to enhance stability in the environment is described, suggesting
a potential role for these fibrils in transmission dynamics. This represents the first pro-viral host
factor identified in the context of EBOV sexual transmission and may represent a viable target for
therapeutic options moving forward.
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Section 4.4 – Materials and methods for preliminary work
This section provides materials and methods information for experiments not described in Section
3.4.

ZIKV infection assays. A549 cells were plated at 1.5e4 cells/well one day prior to infection. ZIKV
MR766 or ZIKV Mex 2-81 (Susan Weiss, U. Pennsylvania) were diluted in DMEM-10 in the
presence or absence of SEVI and used to infect cells at MOI 1 as calculated by plaque assay on
Vero cells. After 1 h, infection medium was replaced with fresh DMEM-10. After 16-20 h, cells were
trypsinized and fixed in 2% paraformaldehyde for >20 min. Cells were permeablized in 0.1%
saponin in FACS buffer (1% BSA in PBS) for 25 minutes, then incubated in FACS buffer with
saponin with the “pan-flavivirus” 4G2 antibody for 1 h, then anti-mouse AF647-conjugated
secondary antibody for 1 h. Infection was quantified by flow cytometry.

Protease treatment. rVSV-EboGP-mCherry was diluted in serum-free DMEM. TPCK trypsin or
proteinase K were added to final concentrations of 50 μg/mL or 20 μg/mL, respectively. The virus
was then incubated for 30 minutes at 37°C. Digestion was halted with DMEM-10 containing
soybean trypsin inhibitor or DMEM-10 alone. Afterward, virus was titered by TCID50 on Vero cells.

Antibody neutralization. rVSV-EboGP-mCherry was incubated with SEVI, then added to serial
dilutions of anti-EboGP antibodies (gift from Erica Ollmann-Saphire, Scripps Research Institute) for
1 h at 37°C. Mixtures were then used to infect Vero cells for 1 h. Afterward, infection medium was
replaced with fresh DMEM-10 and the infection was permitted to proceed for 12 h total. Cells were
trypsinized and analyzed by flow cytometry for percent infection, then relative percents infection
were used to calculate IC50 values (GraphPad Prism).

DC-SIGN cells. 293 T-Rex DC-SIGN cells were maintained in DMEM-10 without doxycycline. To
upregulate DC-SIGN, the cells were treated for 24 h prior to infection with 2 μg/mL doxycycline.
Inhibitor treatments. HeLa cells were treated with the Src inhibitor PP2 (10 μM) for 1 h prior to and
1 h during infection with rVSV-EboGP-mCherry in the presence or absence of SEVI.
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APPENDIX – IDENTIFICATION OF HOST FACTORS THAT RESTRICT ZIKA VIRUS
INFECTION
Stephen M. Bart1, Kangjian Zhang2, Angelíca Ortiz2, Serge Y. Fuchs2, Paul Bates1
1Department
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In addition to identification of seminal amyloids as a host factor that enhanced EBOV
infection, I have conducted work to identify factors that restrict viral infection. Specifically, I have
developed a system in which factors that promote cell survival after viral challenge can be enriched
from a genome-wide pool. This ongoing work seeks to identify factors that restrict Zika virus
replication. K. Zhang and A. Ortiz in the Fuchs lab assisted in the generation of IFNAR1 KO cells
using reagents developed and produced by me. I conceived and conducted the remainder of the
experiments and wrote this appendix under the supervision of Paul Bates.
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Section 1.1 – Introduction
Zika virus (ZIKV) was discovered in Uganda in 1947 and identified as a member of the
Flaviviridae family. The virus, which was traditionally restricted to Africa and Asia, emerged in
several Pacific islands before spreading to the Americas during the 2015-2016 Zika epidemic. The
epidemic was marked by a sharp uptick in the number of cases of microcephaly, other birth defects,
and Guillain-Barré syndrome, prompting the World Health Organization to declare a Public Health
Emergency of International Concern1–5.
The interactions of ZIKV with host cells are poorly characterized. Several loss-of-function
screens have been performed to identify factors required for ZIKV replication 6–8. Several factors
that inhibit ZIKV replication have also been described; these mainly focus upon the interferon
response. ZIKV replication is antagonized by the action of types I and III interferon9,10, which induce
a signaling cascade leading to the expression of numerous interferon-stimulated genes (ISGs).
These genes, among other functions, encode factors with antiviral activity to inhibit viral replication.
Screens employing cDNAs of various ISGs have been used to identify which factors out of the
hundreds of ISGs act upon specific viruses to limit their replication. The breadth of factors that
affect ZIKV replication is unknown, but IFITM1, IFITM3 and viperin have each been described to
inhibit ZIKV replication11–13. It is further probable that there are cellular factors that are not
necessarily interferon-stimulated that also have antiviral activity. The zinc metallopeptidase
ZMPSTE24 has recently been described to have anti-ZIKV activity in a mechanism involving
IFITMs14. A systematic exploration of factors involved in ZIKV restriction, whether interferondependent or not, has not been conducted.
Recently, CRISPR/Cas9 technology has been adapted to allow for targeting gene
activation. One system, synergistic activation mediators (SAM), uses transcriptional coactivators
derived from NF-κB (p65), HSF1, and VP64 along with a modified guide RNA in order to target an
activating Cas9 to a specific locus and upregulate gene expression. When a pool of cells is
transduced with a library of guide RNAs then challenged with some selective pressure, factors that
promote cellular tolerance to that stress are enriched. This library targets 23,430 genes in triplicate
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for a total of 70,290 guide RNAs. These factors can be identified by comparing the abundance of
each guide RNA in the selected population against unselected cells 15. This technology has
identified that sialic acid-modifying enzymes have anti-influenza activity by reducing receptor
binding16.
This report describes the generation and characterization of cells to perform a SAM screen
to identify factors with antiviral activity against ZIKV.
Section 1.2 – Materials and Methods
Cells and viruses. A549 cells (ATCC) were maintained in F12K media supplemented with
10% FBS (Sigma), 293T (ATCC) and Vero CCL81 cells (gift from Susan Weiss, U. Pennsylvania)
were maintained in DMEM with 4.5 g/L glucose and no sodium pyruvate supplemented with 10%
FBS (Sigma). ZIKV MR766 (gift from Susan Weiss, U. Pennsylvania) and ZIKV Mex 2-81 (gift from
Scott Hensley, U. Pennsylvania) were propogated in Vero cells. Newcastle disease virus-GFP was
a gift from Susan Weiss, U. Pennsylvania.
Plasmids. plentiCRISPR (AddGene) was modified to contain a loxP site within the 5’ long
terminal repeat (lentiCRISPRloxP) by restriction enzyme cloning and insertion of a gBlock (IDT).
Components of the SAM system (lentiviral plasmids encoding dCas9-VP64, MS2-p65-HSF1, guide
RNA library) were acquired from AddGene and the SAM library was propagated according to
AddGene instructions. The gRNA2.0 plasmid was also modified to express GFP in place of the
drug resistance marker.
Lentivirus production and transduction. Lentiviral pseudotypes were generated by
transfecting 15 μg genome plasmid, 10.5 μg pSPAX2, and 3.75 μg VSV G with polyethylenimine
into a 15 cm plate of 293T cells. Supernatants were harvested 24-48 h post-transfection, clarified
by centrifugation, and frozen at -80°C.
qPCR. DNA was extracted from half of a 24-well plate well according to manufacturer’s
protocols (Qiagen Blood and Tissue Kit). 5 μL of DNA was used per reaction along with 2 μL of 5
μM combined F and R plasmids (Cas9, puromycin, or GAPDH), 3 μL water, and 10 μL SYBER 2X
master mix. After qPCR, data were analyzed by ddCt method.
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Flow cytometry. Cells were trypsinized, fixed in 2% PFA, then permeablized for >20
minutes with saponin. Cells were incubated with 4G2 antibody (gift from Sara Cherry, U.
Pennsylvania) for 1 h in FACS buffer (1% BSA in PBS) with saponin (4G2 1:4000) then incubated
with AF647-anti-mouse secondary antibody (1:5000) for 1 h. After resuspending cells in FACS
buffer without saponin, cells were ran on LSRII and data analyzed with FlowJo.
Section 1.3 – Results
A549 cells were selected for the screen because of the cells’ intact intrinsic immune system
as well as the ability of ZIKV to induce cytopathic effect (data not shown). To reduce interferon
signaling, which may result in nonspecific survival of cells and increase screen background, a
modified lentiCRISPR construct was first used to knock out the IFNAR1 gene, a component of the
type I interferon receptor. To avoid downstream “crosstalk” between the nucleolytic Cas9 used for
knockout and the catalytically inactive Cas9 used in SAM, the lentiCRISPR vector was modified
such that the lentiviral genome contains loxP sites within the LTRs (Fig A.1A). After treatment of
cells with Cre recombinase, the genome (including Cas9) is excised, leaving only a single LTR
element integrated into the genome. A549 cells were transduced with lentiCRISPRloxP containing
a guide against IFNAR1, then single cell cloned. Clones were screened for knockout by treatment
with interferon-α and γ; a putative IFNAR1 KO clone (1-4) exhibited phosphorylation of STAT1 in
response to IFN- γ but not α (Fig A.1B). Inactivation of IFNAR1 was further confirmed by cellsurface staining for IFNAR and analyzing cells by flow cytometry (data not shown) and genomic
sequencing of the IFNAR1 gene (Fig A.1C).
IFNAR1 KO clones also exhibited a functional inability to respond to exogenous IFN-α.
Cells were pretreated for 24 h with 500 U/mL IFN-α then infected with Newcastle disease virus that
expresses GFP (NDV-GFP). This virus is exquisitely sensitive to IFN and is used as a biosensor
for IFN activity17. As opposed to wild type cells that become resistant to NDV-GFP infection after
IFN treatment, knockout cells show no difference in infectivity (Fig A.1D). Lastly, knockout cells
were infected with ZIKV MR766 at a multiplicity of infection (MOI) of 0.1 for 3 days. At that point,
the supernatants were harvested, cleared of cell debris by centrifugation, and UV-treated to
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inactivate virus. This supernatant was applied to WT or KO cells for 24 h prior to infection with ZIKV
MR766. While the supernatant led to a decrease in infection in WT cells, no difference was seen
in infection among treated or untreated KO cells (Fig A.1E). This indicates that the cytokines
produced during ZIKV infection of IFNAR KO A549 cells do not induce an antiviral state in other
IFNAR KO cells, a key requirement for screening.
IFNAR KO cells were then transduced with lentiviral vectors containing the dCas9-VP64
and MS2-p65-HSF1 expression vectors as well as Ad-Cre to remove the integrated provirus
genome containing Cas9. After selection with blasticidin and hygromycin, cells were single cell
cloned. Individual clones were then harvested for genomic DNA that was subsequently subjected
to qPCR to identify clones negative for the integrated provirus, as marked by the puromycin
resistance gene. While the parent IFNAR KO cells exhibited high Cas9 and puromycin signal
compared to the GAPDH control, several clones showed ablation of the puromycin signal (Fig
A.2A). These puromycin-negative clones were then screened for the clone that had the highest
activity for upregulation of target genes. Cells were transduced with a lentiviral vector containing a
sgRNA for CD4 as well as a GFP marker and analyzed by flow cytometry. CD4 was chosen
because of the abundance of reagents to detect the molecule as well as its lack of expression on
A549 cells. Cells exhibited a range of expression profiles, including no upregulation, upregulation
in a subset of cells, or full upregulation (Fig A.2B). Two clones exhibited full upregulation, and these
cells were independently transduced with three different guides targeting IRF1, an antiviral gene
with wide activity, again with a GFP marker. ZIKV infection (assessed by immunostaining for ZIKV
E) was compared among GFP- (untransduced) cells as well as GFP+ (IRF1 guide transduced
cells). Clone 1.9 was found to have lower relative levels of infection among GFP+ cells in 2/3 guides
compared to clone 1.6, and thus was selected to proceed for screening (Fig A.2C).
Cells of the Clone 1.9 lineage were renamed SAM cells, were expanded, and transduced
with the guide RNA library containing 70,290 guides at an MOI of 0.2. Library was titered by
counting number of cells following treatment with Zeocin following several rounds of replating at
low densities. Cells were transduced at a level designed to give at least 500 transduced cells per
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each guide. After 7 days to permit expansion and gene upregulation, cells were infected with ZIKV
at MOI 1 or passaged in parallel without infection. After 4 days, the cells were washed vigorously
and harvested for DNA to be used in sequencing (Fig A.3).
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Figure A.1. Generation of IFNAR1 knockout cells. 20
A. Schematic of integrated provirus construct within A549 IFNAR KO cells. Upon expression of Cre recombinase,
the provirus is excised leaving only a single long terminal repeat copy integrated. B. Western blot used to screen
clones after puromycin selection. C. Sequencing from the IFNAR1 locus in parental cells or cloned CRISPR cells.
D. Relative NDV-GFP infection in the presence or absence of interferon-α pretreatment. n=3; mean±SEM, *p<0.05
by repeated measures ANOVA of log-transformed percents infection. E. Relative ZIKV infection in the presence or
absence of conditioned, UV-inactivated supernatant. n=2; mean±SD.
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Figure A.2. Generation of SAM cells for screening. 21
A. qPCR screening of clones after transduction with SAM components and Ad-Cre. Puro and Cas9 signal is relative to genomic
GAPDH and normalized to the clonal IFNAR KO parental cells. Lack of puromycin signal indicates successful excision of
lentiCRISPRloxP cassette; Cas9 signal can be from either lentiCRISPRloxP Cas9 gene or SAM dCas9-VP64 gene. B.
Representative flow plots of SAM clones after transduction with lentisgRNA_CD4_GFP. Red peaks are GFP- cells that do not
have the CD4 guide. Blue peaks indicate cells that express GFP and thus are CD4 guide transduced; n=1. C. Relative ZIKV
infection (quantified by flow cytometry) of SAM clones transduced with IRF1 guides; n=1. D. Relative enrichment for lentisgRNA
sequence (quantified by qPCR) after selection with ZIKV MR766 for 3 days.
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Figure A.3. Schematic for screening A549 SAM cells. 22
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